Antimicrobial Resistance in Colombia under the scope of One Health approach.

Luisa Fernanda Toro-Alzate
Colombia

56th Master of Public Health/International Course in Health Development

Koninklijk Instituut Voor De Tropen (ROYAL TROPICAL INSTITUTE KIT)
Vrije Universiteit Amsterdam (VU)

ANTIMICROBIAL RESISTANCE IN COLOMBIA UNDER THE SCOPE OF ONE HEALTH APPROACH

A thesis submitted in partial fulfilment of the requirement for the degree of Master of Public Health

By

Luisa Fernanda Toro-Alzate
Colombia

Declaration: Where other people's work has been used (either from a printed source, internet of any other source), this has been carefully acknowledged and referenced in accordance with departmental requirements.

The thesis Antimicrobial Resistance in Colombia under the scope of One Health approach is my own work.

Signature: Luisa Fernanda Toro-Alzate ………………………………………………

56th Master of Public Health/International Course in Health Development (MPH/ICHD)
16 September 2019 – 4 September 2020
KIT (Royal Tropical Institute)/Vrije Universiteit Amsterdam
Amsterdam, The Netherlands

September 2020

Organised by:

KIT (Royal Tropical Institute)
Amsterdam, The Netherlands

In co-operation with:

Vrije Universiteit Amsterdam (VU)
Amsterdam, The Netherlands

Table of Contents

List of Tables

List of Figures

List of Panels

Acknowledgements

First, I would like to thank the person who made all this possible: my sister Ana Paulina. Puli, without you, this whole dream of coming abroad to study my master's degree would have been another dying dream. You gave me the strength to continue despite all the negative responses, despite my fears and my strange sense of time. Thank you, thank you, thank you. You are my engine and I hope I have made you proud of me.

Secondly, I would like to show my gratitude to my thesis advisor, who gave me all the support and guidance during the time I spent writing this thesis, even when the pandemic caused us to meet through a laptop. Thank you for all the advices and the feedbacks. I hope all that hard work be reflected in this thesis

I would like to thank my new friends who became my family abroad. Every meeting, every dinner, every brunch, every trip and every coffee (or tea) at KIT will be remembered with all love. To Fio, my dear Peruvian friend, who kept me unharmed during our bike rides, for all the patience and love she showed me every time I felt weak and sad; but also, for all the happiness and joy she brought to my life.

To Nuffic, KIT and ICHD course staff, including coordinators, teachers, administrators, and tutors. Thank you for the opportunity to become a "ChangeMaker" by doing this masters, thank you for sharing your knowledge with us, thank you for the patience and kindness, thank you for every smile and concern. All of you left a mark on my heart that I will carry forever.

To my classmates at ICHD. Thank you all for sharing your experiences, your culture, your language and your knowledge with me. I am blessed to have people like you guys as classmates. Thanks for being so comprehensive when I couldn't make myself understood. We went through this together and now you have a place in my heart.

Finally, I would like to thank my family and friends in Colombia. Your support was very important to me. Thanks for never letting me go.

And for A. I told you before, but I will say it again: thank you. Without you, all this time abroad would have been harder.

GRACIAS, GRACIAS, GRACIAS.

Abbreviations

AMR	Antimicrobial Resistance
CME	Continuing Medical Education
COIPARS	Colombian Integrated Programme for Antimicrobial Resistance
COPD	Chronic Obstructive Pulmonary Disease
DALYs	Disability Adjusted Life Years
DID	Daily Dose Per 1,000 Inhabitants Per Day
EPI	Extended Programme of Immunization
ESBL	Extended Spectrum Beta-Lactamase
FAO	Food and Agriculture Organization of the United Nations
GDP	Gross Domestic Product
GHSA	Global Health Security Agenda
GLASS	Global Antimicrobial Resistance Surveillance System
HAI	Healthcare Associated Infections
HIC	High Income Country
HIV	Human Immunodeficiency Virus
ICA	Instituto Colombiano Agropecuario (Colombian Agricultural Institute)
ICUs	Intensive Care Units
INS	Instituto Nacional de Salud (National Health Institute)
INVIMA	Instituto Nacional de Vigilancia de Medicamentos y Alimentos (National Food and Drug Surveillance Institute
LMIC	Low-and-Middle-Income Country
MCR	Mobile Colistin Resistance gene
MDR-TB	Multi-drug Resistance Tuberculosis
MIC	Minimum Inhibitory Concentration
MoHSP	Ministry of Health and Social Protection
NDM-1	New Delhi Metallo-β-lactamase 1
NNRTI	Non-Nucleoside Reverse Transcriptase Inhibitors
OECD	Organisation for Economic Co-operation and Development
OIE	World Organisation for Animal Health
OOP	Out-of-Pocket
OTC	Over the Counter
PAHO	Pan American Health Organization
ReLAVRA	Red Latinoamericana de Vigilancia de la Resistencia a los Antimicrobianos
SPP	Several species
STI	Sexually Transmitted Infections
USD	United States Dollars
WHO	World Health Organization
XDR-TB	Extensively Drug Resistant Tuberculosis
YLDs	Years Lived with Disability

Glossary

Antimicrobial Resistance: Change in the susceptibility to antimicrobial drugs in microorganisms such as bacteria, viruses, fungi and parasites, making them unaffected by the medications used to cure the infections (1).

Current Health Expenditure (as %GDP): Amount of the current health expenditure expressed as a percentage of GDP. Include healthcare goods and services consumed during each year, and it does not include capital health expenditures such as buildings, machinery, IT and stocks of vaccines for emergency or outbreaks (2).

Disability-Adjusted Life Year (DALY): "Healthy" life years lost. There is the sum of years of potential life lost (YLL) due to premature mortality and the years of productive life lost due to disability (YLD) [DALY=YLL + YLD]. The sum of the DALYS in the population is a reflex of the burden of disease (3,4).

GINI Index: Measure of the extent to which the distribution of income among individuals within an economy have a perfectly equal distribution. Gini index of 0 represents perfect equality and an index of 100 represents perfect inequality (5).

Livestock: Animals (such as cows, sheep and chickens) that are kept on a farm (6). Other sources exclude the poultry of the definition (7), but for this thesis the term used includes poultry as well.

Out-Of-Pocket Expenditure (OOP): Spending on health directly out-of-pocket by households (8).

Over-The-Counter (OTC) medications: Pharmaceutical products that can be acquired without a prescription from a healthcare professional (9).

Poultry: Birds (mainly chickens) bred to commercial or domestic use for meat, eggs and feathers (10,11).

Years Lived with Disability (YLDs): Quantity of years lived by people with a health condition or its sequels (3)

Abstract

Introduction: Colombia shows increasing rates of antimicrobial resistance (AMR) in humans and animals threatening the capacity of the health system along with economic, social and environmental impact. I aimed to explore the determinants that influence the AMR in Colombia using the One Health approach, explore the policies regarding AMR and the infection prevention and surveillance programmes and formulate recommendations to tackle the AMR threat.

Methodology: I performed a literature review, including data published between the period of January 2010 and August 2020. I searched in PubMed, the VU Library and Google Scholar for terms related to AMR and grey literature as well. I screened the articles by quality and relevance to this study. I analysed them using a policy framework that combines the One Health approach with the knowledge, access, use and surveillance on antibiotics.

Results: Colombia shows a high fragmentation of the AMR data, without a real estimation on the AMR infections and antibiotic use in animals and humans. Health professionals have limited training and education in antibiotic use. Although the country has several regulations about antibiotic access and use, and extended surveillance and infection prevention programmes, there is still easy access to antibiotics, high self-prescription rates and a broadened antibiotic misuse.

Conclusion: Colombia has the regulatory tools and the surveillance network to reduce its AMR burden, but the country continues with the same old practices regarding antibiotics.

Recommendations: The country needs to improve both the training of the health professionals and awareness among the general population and farmers about antibiotics to stimulate a reduction of antibiotic use. Lastly, there is a need to strengthen surveillance programmes and law enforcement on AMR regulations.

Key Terms: antimicrobial resistance, antibiotic, regulation, One Health, Colombia.

Word count: 13192

Introduction

"The rise of antimicrobial resistance is a global crisis, recognized as one of the greatest threats to health today".
Dr Margaret Chan, former WHO Director-General, 2016

"Antimicrobial resistance is one of the most urgent health threats of our time."
Dr Tedros Adhanom Ghebreyesus, WHO Director-General, 2019

Antimicrobial resistance is defined as the capacity of a microbe (bacteria, fungi, parasite or virus) to be unaffected by the action of any antimicrobial drug (1). This capacity of the microbes to resist to the antimicrobials was the cause of death for an estimate of 700.000 people worldwide in 2014, and it could be the cause of death of approximately 10 million people worldwide by 2050 if no action is taken (12), without taking into account the economic, environmental and social consequences.

The use of antimicrobials is considered the main driver for antimicrobial resistance, but the problem is complex and involves many other factors, including human and animal health, environment, migration and evolutionary mechanisms of the microbes. For this reason, a multidisciplinary and holistic approach is necessary to tackle the antimicrobial resistance burden; that is when the One Health approach appears in the equation as the tool to face antimicrobial resistance.

As a Colombian medical doctor, I had the opportunity to observe the consequences of antimicrobial resistance on my patients. My commitment to the patients motivated me to improve my medical practice and knowledge every day, but I was a witness of many cases of resistant infections due to bad praxis of my colleagues because of the lack of knowledge in the proper use of antimicrobials. Some years later, one family member started to work on antimicrobial resistance in animals and new ways to improve animal health and meat and dairy production without the use of antibiotics. Our talks about the relationship between antibiotic use in animals, antimicrobial resistance and human health, enforced my previous idea of the need to fight against this global menace, and that is why I chose antimicrobial resistance as my thesis topic.

Some questions came to my mind. What is the burden of antimicrobial resistance in Colombia? Why does the community use antibiotics as candies? Is the government aware of this problematic? Is the community aware as well? Why does the animal industry use antibiotics? What are we really eating? And then, I realize the One Health approach would be useful to answer these questions, as it includes animal and human health in the same system.

Therefore, what I want to achieve with this thesis is to explore the determinants that influence the antimicrobial resistance in Colombia, integrating human and animal health, and what are the current strategies in the country to face the antimicrobial resistance burden. By knowing this, I can provide some practical and feasible recommendations to all the governmental and professional institutions by, together, fight and reduce the antimicrobial resistance in Colombia.

We have the tools. Now, we need actions.

Chapter 1: Background

1.1 Geographic and Demographic Information of Colombia

Colombia is a tropical country located in the northern part of South America, with access to the Atlantic and the Pacific Oceans. Colombia shows a high geographic diversity, with an extensive coast area in the north and west part of the country, the Andean mountain range crossing the territory from south to north and a vast part of the Amazonian jungle in the south and east shared with the neighbouring countries of Ecuador, Perú and Venezuela.

The Colombian population is increasing at a modest pace in comparison with other low-and-middle-income countries (LMIC) (13), with a population growth of 1.5% in 2018. The last National Census, executed in 2018, showed a population of 48,258,949 people; 77.1% living in urban and semi-urban areas (14). The current life expectancy at birth for both sexes is 77 years and the birth rate is 15/1000, the latter showing a progressive diminution in the last 60 years (15).

The leading cause of death among the Colombian people are cardiovascular diseases (150.30 deaths/100.000 people), followed by interpersonal violence and other diseases as diabetes mellitus, COPD, cirrhosis, and neoplasms (16,17) (Table 1). Due to the epidemiological transition that Colombia is facing, the leading causes of death are related to injuries and non-communicable diseases. Communicable diseases were responsible for 32.82 deaths per 100,000 people in 2017. Among these diseases, acute respiratory infections were the first cause of death (19.7 deaths/100,000 people), followed by HIV (5.7 deaths/100,000 people) (17).

	Causes of death		Causes of disability (YLDs)		Causes of most death and disability combined (DALYs)
1	Ischemic heart disease		Low back pain		Interpersonal violence
2	Stroke		Headache disorders		Neonatal disorders
3	Interpersonal violence		Blindness and vision impairment		Ischemic heart disease
4	Alzheimer's disease		Neonatal disorders		Low back pain
5	COPD		Age-related hearing loss		Road injuries
6	Chronic kidney disease		Diabetes		Headache disorders
7	Lower respiratory infections & TB		Depressive disorders		Stroke
8	Road injuries		Oral disorders		Diabetes
9	Diabetes		Other musculoskeletal		COPD
10	Stomach cancer		Neck pain		Congenital defects
		Communicable Diseases			
13	HIV/AIDS & STIs	**14**	Enteric infections	**15**	Respiratory infections and TB
15	Other infections	**15**	Respiratory infections and TB	**18**	HIV/AIDS & STIs
18	Enteric infections	**17**	NTDs & Malaria	**19**	Enteric infections
19	NTDs & Malaria	**21**	HIV/AIDS & STIs	**21**	Other infectious
49	Diarrheal diseases	**22**	Other infections	**22**	NTDs & Malaria

COPD: Chronic Obstructive Pulmonary Disease
YLDs: Years Lived with Disability
DALYs: Disability Adjusted Life Years
TB: Tuberculosis
HIV/AIDS: Human Immunodeficiency Virus/Acquired Immunodeficiency Syndrome
NTDs: Neglected Tropical Diseases

Table 1: Top ten causes of death and disability in Colombia in 2017 (16)

1.2 Socioeconomic Situation

Colombia is classified by the World Bank as an upper-middle-income country, with a current Gross Domestic Product (GDP) of 781 billions USD (18), and a GDP growth of 2.6% annual, showing an average growth in comparison with the countries in the region, a process driven mainly by domestic demand with a strong performance of internal consumption and investment (15,19). The main economic activities that contributed the most to GDP growth in 2018 were defence; services; academic and scientific activities; and industry. The agricultural sector showed slow growth, together with mining. Besides, inflation reached 3.2%, close to the Colombian authorities' internal target of 3% (19). The labour market is showing a deterioration, with increasing unemployment rates from 10.8% in 2018 to 12.7% in the first quarter of 2019 for the major metropolitan areas (19). Sadly, due to the current CoVID-19 pandemic and its economic and social impact, the Colombian economy is entering into a deep recession, with the labour market taking a significant drop, rising the unemployment rates and expecting a GDP decline by 7.9% by late 2020, according to OECD economic outlook (20).

For 2017, the Current Health Expenditure (CHE) was 7% of the national GDP, with an out-of-pocket (OOP) expenditure of 16% of the CHE, the lowest in the Latin America region, meeting the OECD benchmark of 20% CHE (21). The pharmaceutical market in Colombia represents only 0.93% of the annual GDP, with a yearly growth of 1.3% between 2015 – 2016 (22). The main activities are concentrated on the marketing of imported products, including antibiotics, showing the Colombian pharmaceutical market is focused on the internal consumption of medicines (23). The market for generic drugs is growing because of the development of generic products with high standards of quality, diminishing the cost of pharma products (22). For 2010, the total pharma expenditure as a proportion of the CHE was 11.77% (0,82% of the 2010's GDP) (24)

Despite the signing of the peace accord in 2016 between the government and the main guerrilla group in the country, conflict-related violence continues, mainly related to the production and market of illegal drugs (25). The internal displacement of victims of conflict and the current massive migration of Venezuelan exiles fleeing from the humanitarian crisis in their country, are becoming a high burden for the Colombian health system and the economy. According to Migración Colombia, the governmental entity responsible for the Colombian migration affairs, by April 30th of 2020 were based in Colombia approximately 1,788,380 Venezuelans, 763,544 of them with legal migration status and 1,024,836 with illegal migration status (26).

Due to the internal conflict, the slow improvement of the humanitarian status, low economic growth of the last years and the large regional disparities among urban and rural areas, the income inequality in Colombia remain high (GINI index 50.4 in 2018), being one of the highest in the world (5). This inequality can be seen in the access to higher education, health services and as a gender issue based on the low rates of female employment (27).

1.3 Generalities of the Colombian Health System

The Colombian health system is financed mainly by a social health insurance scheme for all the individuals in the country, no matter their income or socioeconomic status. This social health insurance is divided into three regimes: contributory regimen, for people who received an income; subsidized regime, for people without a stable income or any income source; and special benefit regime, for teachers from public schools or universities, army, police force and workers from the national oil company (ECOPETROL) (28). In this system, which is decentralised, the Ministry of

Health and Social Protection (MoHSP) gives a specific amount of money to the insurance companies for every patient insured (named EPS or Health Promoting Entity); every EPS contracts the health facilities to provide health services, including vaccination and preventive/curative services (28,29). These three regimes share the same standard basic benefits package, including drugs, supplies, medical interventions and public health activities (28).

Data from MoHSP showed, by June 2020, 95.97% of the Colombian population was covered by social health insurance in any of the three regimes (30). Therefore, access to medical care in terms of the distribution of doctors is inequitable, as the density of physicians is higher in urban areas, with more concentration of specialised services, in comparison with rural areas. In 2018 there were 2.18 physicians per 1,000 population in Colombia, but Bogotá reached almost four physicians per 1,000 population. Also, the consultations with doctors in 2017 were lower than other countries in the Latin America region (1.9 annual consultations per person on average), a situation probably related to the co-payment requirement and the inequalities in the geographical access to health services (31).

1.4 Current Situation of Antimicrobial Resistance

1.4.1 Antimicrobial Resistance

The WHO defines antimicrobial resistance (AMR) as the change in microorganisms, such as bacteria, viruses, fungi and parasites, to render the medicines ineffective to cure infections (32). This change is a natural and evolutionary response to antimicrobial exposure, but this phenomenon is also seen in the absence of direct antibiotic selection pressure (33). The several resistance patterns act according to the antibiotic mechanism of action (Figure 1) (34). The evolution of these resistance patterns and the lack of development of new antibiotics since the early 2000s worldwide, make the AMR a global public health threat, without any new weapons to face it (35,36).



Figure 1: Antibiotic targets and mechanisms of resistance (34)

Antimicrobial resistance has several "modifiable" drivers with different levels of contribution (Figure 2), being the misuse and overuse of antibiotics in human and animal health the most important ones, followed by low sanitation measures, suboptimal diagnosis of infections and others (33,37–39). Genetic ways can transmit the resistance among microbes, and AMR microbes can be transmitted human to human or animal to human by several ways like faecal-oral, sexual contact and health care as well. The geographical movement also plays an important role, as colonised or infected people or animals can spread resistant microorganisms locally, regional or worldwide (33,39).



Figure 2: Role of modifiable drivers for AMR: a conceptual framework (33)

1.4.2 Antimicrobial Resistance Worldwide

According to the O'Neill report, there is estimated that 700,000 people are dying every year globally due to drug-resistant infections, including bacterial infections, HIV, malaria and multi-drug resistant and extensively drug-resistant tuberculosis (MDR-TB and XDR-TB), microbes of international concern (12) (Figure 3). In 2016, deaths attributable only to MDR-TB and XDR-TB were almost 107,000 worldwide, and approximately 20,000 were related to HIV and MDR/XDR tuberculosis concomitant infections (40).

In the European region in 2015, there were almost 700,000 cases and 33,000 deaths due to infection by drug-resistant bacteria, causing 170 DALYS per 100,000 population. 115 (67.9%) of the total DALYS per 100,000 were caused by infections related to bacteria with extensive resistance to antimicrobials, including carbapenem-resistant *Pseudomonas aeruginosa* and third-generation cephalosporin-resistance *Klebsiella pneumoniae*. Estimations showed that 63.5% of infections due to AMR bacteria were associated with health care (predominantly hospitals and other health care settings). In this region, the countries with a higher burden of AMR were Greece and Italy, with DALYS > 400 per 100,000 population (1,627 and 10,762 attributable deaths respectively) (41).



*Enterobacteriaceae include: *Klebsiella pneumonia, Escherichia coli, Enterobacter spp., Serratia spp., Proteus spp.,* and *Providencia spp, Morganella spp.*

Figure 3: Bacteria of international concern and mandatory report to WHO (Adapted from WHO) (42)

Asia and Pacific are regions with a population in growth and high-density cities in place, that can act as a giant reservoir of antibiotic-resistant pathogens (43). Two examples of this were the emergence of the New Delhi metallo-beta-lactamase 1 producing (NDM-1) *E.coli* in India in 2009 and the colistin-resistant Enterobacteriaceae in China in 2016, both bacteria with a worldwide spread (44). Also, both China and India are countries that keep almost one-third of the worldwide incidence of rifampicin-resistant TB (43). In Thailand, at least 43% of the deaths in patients with nosocomial infection are due to AMR bacteria (45).

The trends of AMR in Africa can be divided per region. In West Africa, *S aureus* and *K pneumoniae* show high resistance to first-line treatment antibiotics, which are used according to the syndromic approach instead of the culture-based approach (46). East Africa shows a similar resistance trend, with a high burden of resistance to ampicillin, ceftriaxone and gentamicin; the most commonly used antibiotics for empirical treatments (47). A systematic review made in the sub-Saharan Africa region showed a high prevalence of resistance for tetracycline, trimethoprim/sulfamethoxazole and chloramphenicol in that area, commonly used antibiotics as treatment for *Salmonella typhi* infection (typhoid fever) and *H influenza* infection (48). For HIV, the resistance situation is not better: in a continent with the highest prevalence of HIV in the world (almost 26 million people) and with nearly 500,000 deaths due to AIDS in 2018 (49), the pre-treatment NNRTI (non-nucleoside reverse transcriptase inhibitors) resistance has increased 23% in southern Africa, 17% in eastern Africa and 17% in western and central Africa, in comparison to 11% in Latin America (50)

Therefore, Africa is still facing another branch of antimicrobial resistance: Malaria. This parasitic disease caused 719,600 deaths worldwide in 2017 (40). In 2018, 93% (213 million) of malaria cases and 94% of the malaria deaths were in the African region, and four of the five countries accounted for nearly half of all malaria cases worldwide are in Sub-Saharan Africa. As *Plasmodium falciparum* is the most prevalent malaria parasite in Africa (99,7% of malaria cases), its resistance patterns become a public health threat, including both antimalarial drug resistance and insecticide resistance (51). *P falciparum* shows widespread resistance to chloroquine (only useful in *non-falciparum Plasmodium*), pyrimethamine, proguanil, and sulfadoxine, which currently need to be used in combination with other antimalarial drugs to be moderately effective (52).

Regarding AMR in animals, as a result of the global expansion in livestock products consumption, countries like China and India are increasing the use of antibiotics on animal-based food production to maintain animal health and increase growth (53). This constant use of antimicrobials increases selection pressure on bacteria to become resistant (39,53). Asia as the home of the 56% of pigs and 54% of the chickens in the world, have the higher global AMR prevalence in *E coli, Campylobacter* spp, nontyphoidal *Salmonella* spp, and *Staphylococcus aureus* to the most commonly used antibiotics in animal production (tetracyclines, sulphonamides and penicillin) and human health (ciprofloxacin, erythromycin, third and fourth generation cephalosporins, linezolid and gentamicin), in contrast with other world regions like Africa and Latin America, where the AMR prevalence in animals is lower. Hence, Asia and America regions have the highest rate of colistin resistance in the world (54).

1.4.3 Antimicrobial Resistance in America

In North America, the United States (US) presents 2,868,700 infections by AMR microbes and 35,900 deaths due to AMR infections every year. *Clostridioides difficile*, bacteria that infects patients under antibiotic treatment, and it is related to AMR burden, causes 223,900 cases and 12,800 deaths in hospitalised patients yearly (55). Canada, by its side, shows an increase on the colonization rates by carbapenemase-producing microbes for both community and hospital settings and doubled the rate of community infections by methicillin-resistant *Staphylococcus aureus* (MRSA) infections coming from the community between 2014 – 2017. Thanks to the Canadian surveillance programmes, the all-cause mortality rates among patients with AMR infections caused by carbapenemase-producing *Enterobacteriaceae, Clostridioides difficile* and MRSA are decreasing (56)

For Latin America, the situation does not differ too much. Between 2000 - 2014, the Latin American Network for Antimicrobial Resistance Surveillance (Red Latinoamericana de Vigilancia de la Resistencia a los Antimicrobianos, ReLAVRA*)* reported 2,632,041 isolates of AMR microbes among all the countries members of the network, being the most isolated *E coli* and *Staphylococcus spp*. (57). The LATAM SENTRY programme, an AMR surveillance programme funded JMI labs in 2011, showed that Peru (72.2%), Chile (30%), Argentina (30.7%) and Venezuela (30.6%) had the higher AMR rates in the region for *S aureus*, Brazil (25.7%) and Mexico (26.5%) for enterococci and Mexico (84.8%) and Venezuela (81.2%) for *S pneumoniae* (58).

Similarly, a review with data recollected between 2004 – 2010 showed the prevalence of ESBL-producing *K pneumoniae* was higher in Latin American countries than other continents (59). ReLAVRA data shows by 2016, *K pneumoniae* drug-resistance rates were higher of 50% in Brazil, Argentina, Paraguay, Bolivia, Ecuador and Perú (57). The prevalence of ESBL-producing *E coli* was also higher in Latin America, only exceeded by the Asia/Pacific region (59). According to LATAM SENTRY data, by 2011, Colombia and Venezuela (10.2, 12.5%) showed the highest AMR rates for *Enterobacter* *spp*; and Guatemala (75.8%), Peru (68.8%) and Ecuador (55.6%) the highest AMR rates for *P aeruginosa* (58).

The US and Canada show complete data regarding AMR in animals. The US reported increasing rates of AMR in *Salmonella* and *Enterococcus* in cecal samples taken from chicken, turkeys and beef cattle. Also showed the alarming increasing rates of *Enterococcus, E coli, Campylobacter* and *Salmonella* MDR from food and animal samples, reaching prevalence from 9.5% to 18% in MDR *Salmonella* recovered from chickens and 7% to 15% in MDR *Campylobacter* isolated from beef cattle between 2015 – 2017 (60). In contrast, Canada showed a decrease in the prevalence of ceftriaxone resistance in *E coli* (28% in 2013 to 6% in 2017) and Salmonella *spp* (over 20% in 2013 to 6% in 2017) coming from isolates taken on poultry and chicken meat (56).

The main hotspots of drug resistance in Latin America are the south coast of Brazil and the areas surrounding Mexico City, but Uruguay and eastern Brazil are showing the trend to be emerging AMR hotspots as well. Still, the data regarding AMR in animals are limited in Latin America, even if countries like Uruguay, Paraguay, Argentina and Brazil are meat exporters and should have more robust surveillance networks (54).

1.5 The One Health Approach

According to the One Health Initiative Task Force, One Health is defined as "the collaborative efforts of multiple disciplines working locally, nationally, and globally, to attain optimal health for people, animals, and our environment" (61).

The concept of One Health is ancient. Its origins started in the Greek "golden age" with Hippocrates (c. 460 – c. 377 BC), who held the theory that the exposition to environmental factors could cause disease. During roman ages, Galen postulated the relationship between the balance of the four "body humours" and the environment. During the Renaissance, various European physicians promoted this theory by linking the outbreaks of diseases like the plague and "the fever" with exposure to humid areas and insects (62).

The cholera outbreaks during the Victorian period, that crossed the world from the Ganges River delta region in India until London and Newcastle in the UK passing by Russia and the Baltic region, showed the relationship between the environment, the low hygiene measures and human travelling and migration as propagation factors of infectious diseases (62).

In the Modern ages, physicians and microbiologists like John Snow and Louis Pasteur developed the "Germ Theory", in which an etiologic agent causes infectious diseases. Later on, in the twentieth century, Calvin Schwabe, an American veterinary and epidemiologist, developed the concept of "One Medicine", describing the relationship between veterinary medicine and human wellbeing. During the '70s, the Canadian International Development Research Centre developed the concept of EcoHealth (Ecosystem Health), a system promoting human health and wellbeing focused on social and ecological interactions (62). After all these stages, One Health was developed by CDC, PAHO and WHO at the beginning of the twenty-first century as a public health strategy of multi and interdisciplinary collaborations in all aspects of health care for animals, humans and the environment (62,63).

One Health approach recognizes human health and its connections with animal and environmental health. This means that many factors can modify the interaction between people, animals, plants and the general environment (64). The approach includes several areas, such as agricultural production and land use, climate change and its impact on health, disease surveillance and prevention, human-animal relation, cultural practices, and legal framework (65,66). One Health is holistic and transdisciplinary, with the incorporation of multisectoral expertise dealing with the health of humans, animals and the environment (Figure 4) (66).



Figure 4: The One Health holistic approach (66)

Within One Health approach, AMR has a unique position as it is focused mainly on the reduction of antibiotic use in food animals but also needs to address the complexity of the AMR problem as resistant microbes are present in the aquaculture, environment and wildlife (67).

Antimicrobials are used in human, animal and environmental health and food production in several ways. Insects and plants are treated with antibiotics to prevent and treat bacterial infections (such as "fire blight", a bacterial disease in apples and pears caused by *Erwinia amylovora*); humans and animals are treated with antibiotics as infection treatment, prophylaxis (i.e. prevention of meningococcal infection in groups or prevention of infection post-surgery), and in the treatment of viral infections (68,69).

Therefore, in the food-production market, antimicrobials are used in a different, not only used as a therapeutic tool against infections, but also as prophylaxis and metaphylaxis (giving antibiotics to healthy animals who live in the same environment with the diseased animals) and as a growth promotion factor (Table 2). The non-therapeutic use of antibiotics in the food production sector often utilize suboptimal doses of antibiotics for a long amount of time, accounting for the bulky number of antimicrobials used worldwide (68). These uses can induce AMR as the colistin case, an antibiotic initially banned for the systemic use in humans due to its toxicity but used extensively as a growth factor in livestock, promoting a significant antimicrobial resistance in humans, in which now is used as a "last-resource" antibiotic (39,68) and the presence of the plasmid in water sources and wildlife due to environmental contamination (70).

Veterinary Use	Human Use
Population often treated	Individuals treated
Diagnostic pathway may involve post-mortem	Post-mortem avoided
Cost of treatment very important	Cost less important
Range of bodyweights can be several orders of magnitude across different species	Limited range of weights
Dose rates for oral treatment depend on feed or water intake	Oral dose usually based on age (less frequently on body weight)
Many different monogastric and polygastric species	Only one gastrointestinal type
Withholding period must be observed	No withholding period
Parenteral injections administered to sites that can be trimmed at slaughter	Parenteral injections administered to sites with least pain or reactivity
Long-acting injections preferred	Short-acting injections or oral preparations are normal practices
Prevention of infection most important factor	Treatment of infection usual practice
Diagnosis supported by disease behaviour in population	Diagnosis based on individual features
Majority of animals are young	Full spectrum of ages, neonate to geriatric
Chronic comorbidities rare	Chronic comorbidity common in older individuals

Table 2: Differences in the use of antimicrobial agents in human and veterinary health (Adapted from Page and Gautier, 2012) (71)

These situations made AMR a burning topic on the Global Health Security Agenda (GHSA). The GHSA was set up by the US government, partner nations and international organizations in 2014 to assemble efforts in the prevention, detection and response of infectious disease outbreaks worldwide. AMR was one of the identified critical challenges by this Agenda (35) because, without effective antibiotics, people can die because infectious diseases which have cure already or had been eradicated.

Besides, global food security and safety are at risk due to the extensive use of antimicrobials in livestock, poultry, aquaculture and agricultural production. Also, global economic security may be affected by increased health spending and its impact on global GDP, with an estimated decrease between 1.1 - 3.8%, leading to a projected 28.3 million increase in the number of people in extreme poverty by 2050, with the majority of these people living in LMIC (26.2 million) (69,72)

To address these concerns about AMR, food security and safety and infectious diseases risk, the Food and Agriculture Organization of the United Nations (FAO), the World Organization for Animal Health (OIE) and the WHO developed, in 2010, a tripartite collaboration using the One Health approach. This collaboration was made to promote responses between multiple sectors and to provide guidance about food safety hazards, zoonoses and animal diseases, and other public health threats for human, animal and ecosystem interface (Panel 1) (73,74)

Panel 1: The FAO-OIE-WHO Tripartite Alliance

Despite the FAO, the OIE and the WHO have worked in combination to address health threats to humans from animals for years, in 2010 the three organizations decided to facilitate a formal alliance, following the One Health vision. This Alliance has the vision of “A world capable of preventing, detecting, containing, eliminating, and responding to animal and public health risks attributable to zoonoses and animal diseases with an impact on food security through multi-sectoral cooperation and strong partnerships.” (73)

In 2011, the Tripartite identified three main topics – antimicrobial resistance, rabies and zoonotic influenza – as examples of the importance of a multi-sectoral collaboration to successful risk management (75).

As a result of this alliance, the three Organizations decided to develop the Global Action Plan on Antimicrobial Resistance. Furthermore, this Global Action Plan is used as a guide to the Organizations to the development of their respective strategic work plans, ensuring alignment of the actions in every level (75).

For rabies, the Tripartite developed a framework for rabies elimination in December 2015. This framework fosters stronger partnerships between the sectors, with the idea that disease control in animals results in the reduction of human exposure and mortality (75).

For zoonotic influenza, the Tripartite and its partners are working in the improvement of surveillance systems. With this improvements, the time between the outbreak occurrence, diagnostic and reporting could be in days or even hours, depending on the country, using data from the OFFLU (the OIE/FAO Network of Expertise on Animal Influenza) in collaboration with the WHO Global Influenza Surveillance and Response System (GISRS) (75).

The Alliance also works in topics related to the implementation of International Health Regulations, assessment of the national capacities for detection and control of health events and strengthen the cooperation between human and animal health systems (75).

Chapter 2: Problem Statement and Justification

2.1 Problem Statement

Antimicrobial resistance is becoming a global public thread, increasing the mortality rates and prolonged illness, with a high impact on the economic, social and environmental aspects (36). According to projections made by O'Neill in 2014, it is estimated if effective measures are not taken to face the AMR burden, by 2050 there will be around 10 million deaths per year related to AMR worldwide, with a reduction of world GDP between 2% to 3.5% (12).

AMR is a natural and evolutive phenomenon that is increasing due to the selection pressure made by the use of different antimicrobial agents in farming and human health, resulting in the adaptation of the microbes to them. Antibiotic use is the main determinant for the increasing rates of antimicrobial resistance (33,37,38). However, AMR is more complex and has additional contributing drivers: the high consumption of antibiotics in animal health for non-therapeutic uses, the migration of humans and animals, the poor sanitation and infection prevention measures and the lack of regulatory policies and the neglected implementation of the existent ones about the antimicrobial use by healthcare and animal production industry (33,76,77). Also, the lack of development on new antimicrobials to replace the current ineffective ones and to treat the now resistant microbes brings a sense of urgency to tackle this global thread (36).

The antimicrobial use in animal and agricultural production, together with the use of metals in agriculture as antimicrobials (copper is used as an antifungal and antibacterial agent in agriculture), the pharmaceutical industry pollution and the non-environment-friendly sewage systems for the human wastes, can add more selective pressure to the microbes in the soil and water. These factors contribute to both the rise of AMR and environmental contamination as well (33).

Colombia, as an upper-middle-income country, is trying to do its best to tackle the increasing AMR burden, in comparison with other countries in the region (78–81). Although, the country remains in high risk regarding AMR, not only because of the contributing drivers about antimicrobial use and the migration from countries that have not strong AMR programmes, but also the fragmented information about AMR in the country, the perception about antibiotic and health among the general population, the limited training and education among the medical doctors and veterinarians, and the lack of antimicrobials stewardship programmes in the health facilities countrywide (80).

2.2 Justification

The new strategic plan promoted by the World Health Organization in the Global Action Plan on Antimicrobial Resistance, published in 2015 and notoriously mandatory for member countries, is now on implementation stage in Colombia (76). Previous regulations have not had a significant impact in the country, even addressing strategies for the use of antimicrobial drugs in human and animal health, the dispensing of medicines, and surveillance methods for antimicrobial-producing laboratories (76,82).

Despite the knowledge on the AMR situation and its contributing drivers, many gaps remain in the search for measures to contain and face AMR. The diversity of the pathogens showing resistance (viral, bacterial, fungal and parasitic) make the development of new infection prevention programmes harder. Also, AMR related to bacteria causes life-threatening infections which can be acquired in hospital and community settings, but there is a lack of knowledge about the spread trends, evolution and impact of these infections (36).

The objective of this thesis is to explore the determining drivers for AMR in Colombia from the perspective of One Health, the access and use of antibiotics in the country, the policies related to the use of antimicrobials in human and animal health and the strategies for disease prevention through infection prevention programmes, to identify gaps in the performance of the current policies and surveillance programmes. It is important to highlight that this thesis is focused on AMR from the antibiotic perspective, as antibiotics are the main antimicrobial implicated in the AMR problem.

2.3 Objectives

2.3.1 Overall Objective

To explore the determinants that influence the antimicrobial resistance in Colombia using the One Health approach and identify gaps on the performance of the current policies and surveillance programmes to formulate recommendations to the Ministry of Health and Social Protection, Ministry of Environment and Sustainable Development, Ministry of Agriculture and Rural Development, Ministry of Education, Medical, Dentist and Veterinarian associations, the Colombian Agriculture Institute (ICA), National Health Institute (INS), the National Institute for Food and Drug Surveillance (INVIMA) and the Colombian Corporation for Agricultural Research (AGROSAVIA).

2.3.2 Specific Objectives

a. To explore the current status of antimicrobial resistance in Colombia in both human and animal health, taking into consideration the human and animal use of antimicrobials.
b. To identify the contributing factors for antimicrobial resistance related to antibiotic production, access, and use in both human and animal health sectors in Colombia.
c. To assess the Colombian infection prevention strategies in both human and animal health and its relationship with the Global Action Plan on Antimicrobial Resistance.
d. To describe the current regulations and surveillance programmes of antimicrobial resistance in Colombia and its link with transnational surveillance programmes.
e. To formulate recommendations to the Colombian Ministry of Health and Social Protection, Ministry of Agriculture and Rural Development and the other implicated stakeholders.

2.4 Methods

2.4.1 Study Type

The methodology used for this thesis was a literature review, which included data published between the period of January 2010 and August 2020. This literature reviewed the determinants that influence the AMR in Colombia, an exploration of current regulations, infection prevention strategies and surveillance programmes to address the AMR problem in Colombia and how these can be related under the One Health approach.

2.4.2 Search Strategy

The sources for this literature review were the Colombian MoHSP reports and current and previous policies, strategic plans and guidelines; these are available on the MoHSP website. Also, policies and guidelines about environment and animal health were taken from the Ministry of Environment and Sustainable Development, Ministry of Agriculture and Rural Development, INVIMA and to the Colombian Agriculture Institute (ICA) websites.

The search engine used was Google Scholar, and the online academic databases used were the VU library and PubMed; these were used to search online materials from national and international sources, mainly peer-reviewed articles. The snowballing technique was also used to find articles related to the topic. Additionally, information about international policies and programmes were taken from the WHO and PAHO websites and from the literature of other countries with a similar context in Latin America. The keywords used for the search strategy were used in combination and separately in the search engines, using both languages English and Spanish. The full list of search terms can be seen in Table 3.

Antimicrobial resistance	**AND**	Colombia low- and middle-income countries	**AND**	Animal Antibiotic Antimicrobial use Burden Epidemiology Global Health Security Agenda Healthcare Human	Infection Livestock One Health Over the counter Policy Prescription Prevention Regulation Surveillance Self-medication

Table 3: Search terms used on the search strategy

2.4.3 Inclusion and Exclusion Criteria

The inclusion criteria for choosing the sources were based on their information about AMR in bacteria and antibiotic use in LMIC and Colombia; studies were conducted with both quantitative and qualitative methods. The time frame was the last ten -10- years. After finding several articles using the search terms, the full pool of articles was screened by title, relevance and abstract content following the inclusion criteria. As several policies were developed before 2010, they were also included in the review due to their relevance.

2.5 Study Limitations

The limitations of this study were principally the limited AMR information in Colombia and the inexistent information about mortality and morbidity related to AMR in human or animal health. This study was limited to studying AMR from the One Health perspective for antibiotics in human health and livestock (cattle, poultry, pigs). Therefore, information about antibiotic use in fish farming and farming of other species was not in the scope of this study.

2.6 Analytical Framework

The analytical framework used for this literature review was the one proposed by Dar et al. (77) to explore the national and regional policy interventions to combat resistance, developed in 2016. The utility of this framework relies on the conjunction of public health and society challenges to tackle AMR. The framework shows the necessity of a solid foundation based on knowledge generation and continuous research and innovation (knowledge base); this foundation supports access to antimicrobials to achieve its proper use. Above this, there are two main strategies: the responsible use (based on the demand and supply of antimicrobials among health workers, veterinarians, animal products market and community) and the infection prevention (based on the necessity to reduce the need of antimicrobials in human and animal health). The surveillance and monitoring system is used to watch and measure the progress of the AMR and control strategies. All this is framed under the One Health approach, that embrace human, and animal health (77) (Figure 5)



Figure 5: Policy framework for sustainable access to effective antimicrobials (77)

Chapter 3: One Health in Colombia

Before 2007, there was not any programme related to One Health in Colombia. The surveillance programmes were focused only on human health and were fragmented; for animal and environmental health, there was not any surveillance or working group (83).

In 2007, stakeholders including the Colombian Corporation for Agricultural Research (CORPOICA, now AGROSAVIA), the Colombian Institute of Agriculture (ICA), the Food and Drug Surveillance Institute of Colombia (INVIMA), the Colombian National Institute of Health (INS), several research groups, universities, retailers and the poultry industry, met their interest in AMR and conformed the Colombian Integrated Programme for Antimicrobial Resistance (COIPARS) (83). This programme started as a 4-years programme to follow the AMR in zoonotic bacteria from any animal, environmental or human source, and to follow the antimicrobial use in humans and animals (84). This programme was the first step towards One Health.

Nowadays, with the setting-up of the Colombian National Plan for Response to Antimicrobial Resistance, the One Health approach has a better field to grow. Currently, two programmes are working on One Health in Colombia: The One Health Consortium, created by the Wisconsin Madison University from the US, the National University of Colombia and Ruta N Corporation, an innovation hub recognized worldwide, to offer diagnostic tools and research in human and animal health (85). The second one is the One Health Net Colombia, an academic and scientific community funded by the Cordoba University (Montería, Colombia) to inform and communicate the One Health principles between the Colombian academic and research societies (86).

Chapter 4: The Status of Antimicrobial Resistance in Colombia

Colombia has not been oblivious to the problem of AMR. The country has been targeted by the most resistant and infectious microbes in the last 20 years, including NDM-1 *K pneumoniae,* mobile colistin resistance (mcr-1) gene in *Salmonella enterica* and *Candida auris* (76) (Panel 2)

The surveillance report of the INS between 2012 – 2014, showed how resistance rates were raising, with an increment of the AMR for the third generation cephalosporins in *E coli*, reaching 26.3% of resistance in ICUs, in comparison with previous years. Also, between the Enterobacteriaceae, the most frequently carbapenemases were KPC (Klebsiella Pneumoniae Carbapenemases-producing) and NDM-1 (New Delhi metallo-B-lactamase), sharing this pattern with *P aeruginosa* (87). Besides, according to RELAVRA data, in 2016 Colombia had resistance rates between 25% - 50% for oxacillin in Staphylococcus species, a common antibiotic used to treat infections caused by this widely spread and often mortal bacteria (88)

Panel 2: The emergence of NDM-1 carbapenemase, mobile colistin resistance (mcr) gen, and *Candida auris* in Colombia

New Delhi metallo-β-lactamase 1 (NDM-1)

The NDM-1, the latest carbapenemase described and with extended resistance to all beta-lactam antibiotics except aztreonam, were reported for the first time in 2009, in an Indian-Swedish patient who had received antibiotic treatment in India after developed a large gluteal abscess and a decubital ulcer (89). After a worldwide spread, NDM-1 were reported in Colombia for the first time in 2011, when it caused an outbreak in a neonatal unit in Bogotá (90). Following reports demonstrated the presence of this enzyme in gram-negative bacteria around the Colombian territory (91,92).

Mobile colistin resistance (mrc) gene

The polymyxins (such as colistin) were discontinued in the 1970s due to the high risk of neurotoxicity and nephrotoxicity in humans, but it remained used in animal health as treatment and prophylaxis against Gram-negative infections and as a growth factor (39). After its reintroduction in 2015 as the "last option" in the treatment of extensively drug resistance (XDR) gram-negative infection, where carbapenems are useless, the mrc-1 gene was identified for the first time in E coli isolates in China in 2016 (93,94). Following a fast worldwide spread, the mrc gen was identified in Latin America in infected animals (8.7%), food samples (5.4%) and humans (2%), mostly mcr-1 but also other types as mcr-3 and mcr-5 (93). Colombia showed a high prevalence of mcr gen, being the fourth in the region (2.4% of the region's reports, all in clinical isolates) and it is the only country with the presence of mcr-5 (93). Currently, the use of colistin in livestock in Colombia is banned (95)

Candida auris

Candida auris, a yeast often associated with hospital outbreaks, was isolated for the first time from the external ear canal of a 70-years old Japanese woman in Tokyo in 2009 (96). After the first isolate, *C auris* infections were widely reported from Korea to the US and Venezuela. This yeast has three crucial implications: can cause invasive candidiasis, its laboratory identification is challenging, and it is often described with a multidrug-resistance pattern. In Colombia, the first report was in 2015, but since then, several reports were made in different regions of the country (97–99). The report of any *C auris* infection is mandatory in Colombia (98)

Between 2012 - 2018, the INS Laboratory received 4599 isolates from health facilities nationwide to confirm the presence of carbapenemases. The most frequent microorganisms were *Enterobacteria* and *Pseudomonas aeruginosa,* followed by *Acinetobacter spp*. In this isolates, 93% showed a resistance pattern, being carbapenemases the most frequently found (83.2%) either KPC, NDM, VIM or OXA-23. The most affected regions were Antioquia, Cauca, Cundinamarca and Santander, the regions with higher economic development in the country (100).

In ICUs and hospitalization services countrywide, data from WHONET in 2018 in isolates from healthcare-associated infections (HAI), showed K pneumoniae had resistance to third-generation cephalosporins in 34.7% (ICUs) and 40.3% (hospitalization), decreasing rates in comparison with 2017. In contrast, E coli showed an increment in the AMR isolates in comparison with the previous year (24% for ICUs and 33% for hospitalization). Acinetobacter baumannii, a bacteria non-lactose fermented, showed the highest resistance to carbapenems, being 53.4% for imipenem and 46.7% to meropenem, but in decreasing regarding previous years (100,101).

On the other hand, in the Colombian meat industry from poultry, swine or cattle origin, it is common to find meat products contaminated with bacteria such as *E coli, Salmonella sp, Shigella* and *Campylobacter*, pathogens that show high resistance profiles and can be causal agents of diseases transmitted by food, like acute gastroenteritis, in humans (102). For *Campylobacter*, for example, the handling and consumption of poultry meat is the leading risk factor for acquiring human campylobacteriosis, whose treatment includes the use of macrolides, fluoroquinolones and tetracyclines, antimicrobials used in animal production as well, and which have shown resistance profile already (39,83).

Several studies had shown the presence of AMR bacteria in animal-based food in Colombia, including dairy and poultry meat. In Entrerríos, a village specialized in dairy, a study found the presence of extended-spectrum beta-lactamase (ESBL) producing Enterobacteriaceae bulk-tank milk (3.3%), in which 70% of the farms reported the use of antibiotics (103). In the Sumapaz region, a study showed a prevalence of *E coli* and *S aureus* multidrug-resistant in 75% of the studied dairy farms (104).

Another study conducted in two Colombian states in which poultry farming is the main economic activity (55% of the national production), at least 41.4% of the studied farms had the presence of *Salmonella*, and all the isolates showed resistance to minimum 2 of 15 antibiotics tested; in this case, all the isolates in the study were classified as multidrug resistant (105). In these studies, the use of antibiotics and the low infection prevention measures were related to the presence of multidrug-resistant bacteria on the farm products (103–105). Similar findings of the use of antibiotics without prescription can be seen in the poultry industry, where the antibiotics have not only therapeutic use, but also as a growth factor, despite the regulations about it, and in subtherapeutic of over-therapeutic doses (106).

In contrast, the presence of AMR bacteria is not only at the farms. One study conducted in several chicken meat retailers in Bogotá D.C showed the presence of *Salmonella, E coli* and *Enterococcus spp* in chicken meat, all of them with resistance to several antimicrobials, including quinupristin-dalfopristin, an antibiotic used to treat severe infections in humans when vancomycin resistance is present (107).

Chapter 5: Production, Access and Use of Antimicrobials in Colombia

5.1 Production of antimicrobials in Colombia

The production of antimicrobials can contribute to the development of AMR in two ways: first, the inappropriate disposal of the manufacturing waste of antimicrobials and, second, the low quality of the antibacterial drugs which can contain too little of the active ingredient that works as antimicrobial (108). Regarding the quality of the antimicrobials, several studies *in vitro* and *in vivo* had described the equivalent action between antimicrobial drugs used in Colombia, brand and generic, considering that the health care provider takes the choice to acquire brand or generic antibiotics according to its agreements (28).

In the case of ciprofloxacin, the bioequivalence and the action *in vitro* and *in vivo* were similar between the brand and generic medication produced in Colombia (109). In contrast, for the cases of meropenem, oxacillin, gentamycin, vancomycin and piperacillin-tazobactam (110–114), antibiotics extensively used as a treatment for human infections in Colombia (115), with bioequivalence studies showed the same equivalence between the brand and generic drugs available (national-produced and imported), there had therapeutic non-equivalence, which can remain undetectable under the current regulations. This disparity between pharmaceutical equivalence, bioequivalence and therapeutic equivalence can lead to therapeutic failure, AMR and increase of health care expenditures (113,114).

Since 2016, Colombia has a new regulation regarding the bioequivalence in medicines, with a list of drugs with mandatory bioequivalence study, but in this list, there is not any antimicrobial drug (116,117). This action can discourage the research in antibiotic bioequivalence and prolong the current knowledge gap regarding antibiotic efficacy (118).

5.2 Access to Antimicrobials

5.2.1 Over-the-counter (OTC) sales of antibiotics in Colombia

In Colombia, over-the-counter (OTC) medications are the pharmaceutical products which the consumer can acquire without a prescription made by a medical doctor, dentist or veterinarian. These products usually are used for prevention, treatment or relief of symptoms of some "light diseases", easily recognisable by the patients. The main characteristics of these medications are two: i) the voluntary administration of this drug does not represent a health concern and ii) the existence of this medicament in the pharmaceutical market should be higher than five years (9). In this case, any antibiotic needs a prescription to be acquired (119).

Despite the Colombian government regulating the sales of antimicrobials without prescription in 2005, this practice is still spread among the Colombian population. According to a descriptive study conducted in Bogotá D.C in 2010, 80.3% of the drugstore workers had the intention to sell antibiotics without prescription, and at least 15% of the sellers recommended another antibiotic regarding the initial request (120). Another study conducted in 2009 in the same city showed 43.1% of the participants bought antibiotics without any prescription, 13% of them self-prescribed with antibiotics, and 30.2% received the advice to take antibiotics for a person different from a medical doctor or dentist (121).

In the animal sector, the purchase of antibiotics without prescription is a common practice as well. Two studies made in the dairy and poultry industry showed 70% of the farms use antibiotics prescribed by a veterinary half or less than the times, and only 37.65% of the stores have trained staff to prescribed antibiotics and give recommendations about their way of use. None of the stores gave recommendations about the withdrawal of antibiotics before the slaughter and commercialization of the animal products (103,106).

5.2.2 Knowledge About Antibiotics and Antibiotic Prescription Practices Among Colombian Health Workers

Only licensed medical doctors, veterinarians, and dentists can prescribe antibiotics in Colombia (119,122). To get their professional license, these workers have to complete their bachelor studies and register themselves to the different professional associations (Colombian Medical Association, Professional Council of Veterinary Medicine and Zootechnics of Colombia, Colombian Dentists Association). This license is for life and does not require any updating course or examinations after issued (123). The continuing medical education (CME) activities are not mandatory to keep the license, and its attendance is voluntary (124).

Although medical doctors and dentists receive education and training in antibiotic use during their academic term, 29.6% of the Colombian medical students consider that the quality of the information and education regarding antibiotics use is regular to poor, 43.5% of the medical students consider the training in antibiogram interpretation as insufficient, and 21.4% of the students consider inadequate the training in searching of evidence-based information (125). Also, the knowledge about infection treatment, antibiotic use and toxicity of antibiotics are low among medical students, developing erroneous prescription habits (125).

The lack of knowledge of clinical guidelines plays an essential role in the antibiotic prescription practice among medical doctors. A study conducted among patients with skin infections in two primary care facilities showed 74.8% of the patients received the indicated antibiotic, but 36% of the antibiotics were prescribed in a higher dose than recommended, and 7% of the patients were prescribed with a lower one. In addition, the use of a second antibiotic for the treatment of skin infections was present in 11% of the patients. Also, the fact of prescribing the first antibiotic for intramuscularly use or the second antibiotic for external use was associated with inadequate prescriptions (126).

A survey conducted among general practitioners and specialists showed that 75% of the health professionals were adherent to the stewardship programmes of their hospital. However, only 32% use the local antibiotic guidelines (made by every hospital according to national guidelines by the Ministry of Health and based on international guidelines). Unexpectedly, in this survey, almost 5% of the physicians used antibiotics by the patient's family request (127). There is a strong geographic influence in the antibiotic prescription practices among medical doctors in outpatient consultations: the trend in cities is the use of a single antibiotic, generally on an oral form, being these antibiotics, part of the Access and Reserve group established by the WHO (Annex 1). In the municipalities, it is more common the prescription of two or more antibiotics, mainly in injectable form, being the Watch group antibiotics the most prescribed ones. This practice can be related to low voluntary CME and a lack of following of the clinical guidelines (128).

5.3 Antimicrobial Use in Colombia

5.3.1 Use in Human Health

The WHO Report on Surveillance of Antibiotic Consumption defines antimicrobial use as "data on antibiotics taken by the individual patients" (129). Studies conducted in several Latin American countries showed Colombia has one of the lowest antimicrobial use in the region (8.09 DID, daily dose per 1,000 inhabitants per day), being penicillin the most used antibiotic class in the regular consultation (130), ciprofloxacin in hospitalization services (115) and meropenem in ICUs (115,131). Also showed Colombia has an average use of antibiotics in human health, mainly used for community-acquired infection (58.1% of the total antibiotic use) (132).

Between 2016 and 2017, the use of meropenem in the country's ICUs decreased from 3.12 DID to 2.86 DID, decreasing related to the implementation of antibiotic stewardship programmes. On the other hand, in the country's hospitalization wards, the use of ciprofloxacin increased from 0.8 DID in 2016 to 0.97 DID in 2017. Surprisingly, one of the most isolated and poorest regions of Colombia, Casanare, showed the highest consumption in the country of wide-spectrum antibiotics like meropenem and piperacillin-tazobactam, in both ICUs and hospitalization wards (115).

5.3.2 Use of Antimicrobials Among the General Population

Several factors are related to the antibiotic use outside the one indicated by medical prescription: household "drug-stock", self-medication, and use of antibiotics as a treatment for non-infectious diseases (133–135). The inadequate patient compliance in antibiotic regimes is a driven point in the misuse of antibiotics as well. This poor compliance can be related to the perception of low quality for medical services, together with the short time for medical consultation and the consequent deficient communication between the clinician and the patient, in addition to lack of access to some medical services (133,136,137).

Self-medication is, indeed, a common practice among the general population in Colombia. Two surveys made in two different cities of the country showed between 56.1% and 77.5% of the population practice self-medication for any medication (136,138), and almost 83% consume more of the indicated quantity of antibiotic prescribed regimen (136). Further, 61% of the population manifested the main reason for antibiotic use in self-medication was the successful past-use prescribed or not (136), and 75% of the people use antibiotics as a preferred drug to treat infection, whether viral or bacterial (138). Surprisingly, the self-medication practice was not significantly associated with socioeconomic status; and the relationship between the affiliation to the health system, educational level and self-medication practice seems to be variable between the surveyed population (136,138). The misuse of antibiotics also can be related to short-term regimes self-prescribed and low adherence to antibiotic treatment, causing an early withdrawal. In these surveys, 50% of the population use antibiotics for 1-2 days, 41.4% for 3-4 days and only 6% consume antibiotics for more than five days (5-10 days) (136).

One of the driving reasons for self-medication practice is the storage or "drug-stock" of medicines, including antibiotics, at home. In these surveys, 58.2% of the population store medicines at home (138), being the antibiotic storage a common practice between 8.8% and 14.1% of the population, due to previous use or probably future use (136,138). This data also showed that the home-storage of medicines could increase almost two times the probability of self-medication among people who have this practice (138). The self-storage of antibiotics can incentivise self-medication practice, and the consumption of expired antibiotics stored at home can impact the AMR burden due to the fast loss of their antimicrobial efficacy after their expiration date (139).

The perception of the severity and type of symptoms, the negative perception of the healthcare system and the reliability on relatives and friends' advice about previous antibiotic use, are factors that influence to increase the consumption and self-medication among the general Colombian population (138). People assist to the health care services only when they feel the disease has a moderate to high severity, leaving the self-medication practice to the perceived mild-symptoms (136,138).

5.3.3 Use in Animal Health and Meat Production

Antibiotics are used in extensive and intensive livestock production systems, as a tool to grow healthier animals and produce more and low-cost meat products, especially in cattle, pigs and poultry (71), the three primary sources of meat in the country. This use is mainly due to the risk of incubation of pathogens of the environment during the growing up of animals and distribution of the meat product. The lack of infrastructure for slaughter the animals and affectation in the cold chain for the meat processing are other factors related with the extensive antibiotic use (102). The most important antibiotics used for livestock health are penicillin, streptomycin, bacitracin chlortetracycline, oxytetracycline, and erythromycin; but tetracyclines, penicillin and bacitracin are also used to promote the growth of pigs, poultry and calves (71).

Although the need to use antibiotics in animal health is clear for infection treatment, the use of antibiotics as a nutritional agent or growth promoter and as an infection prevention strategy remains questionable (102). In these cases, it is not possible to prepare a specific dosage regimen based on the Minimal Inhibitory Concentration (MIC) for any bacteria in particular. For antibiotics as growth promoters, some theories talk about the anti-inflammatory and modulation effect that antimicrobials produce on the gut or the possible changes in the gut microbiome (71). For this effect, antibiotics are used as food additives, showing greater body mass and better physiological performance over time (i.e., weight gain) by achieving greater assimilation of the food consumed and increasing muscle mass in less time (71,102). This practice is carried out intensively in poultry and pig production, either continuously and permanently or affecting a specific stage of the animal's development (102).

The use of antibiotics in livestock adds pressure on the bacteria to become multi-drug resistant and can remain on the meat for human consumption, becoming a risk factor in susceptible people to develop allergies, anaphylaxis, or even death (106). In one study conducted in Cartagena, 100% of the samples taken from chicken meat acquired in retailers had the antibiotic lincomycin in high quantity, which is used as a growth promoter (140). In swine meat and organs as liver and kidney, used as human food, another study found the presence of antibiotics such as beta-lactam, aminoglycosides and sulphonamides (141). These findings show the indiscriminate use of antibiotics in the livestock industry and the lack of compliance on the withdrawal times of antibiotics used before slaughter and commercialization of the meat products (47,106,141).

Chapter 6: Infection Prevention in Human Health and Animal Sector in Colombia

6.1 Human Infection Prevention

Many of the infections produced by microbes with high resistance to antimicrobials occur in healthcare facilities, due to the treatment of severely ill and infected patients and their intensive use of antibiotics (142). In this way, following the recommendations of the WHO's Global Action Plan on Antimicrobial Resistance and the third strategic line of the National Plan for Response to Antimicrobial Resistance, the Colombian Ministry of Health developed the Programme of Prevention, Surveillance and Control of Infections Associated with Health Care and Antimicrobial Resistance. This programme works nationwide, and it is aligned with the Public Health Decennial Plan 2012-2021 in the aim "to reduce the infections associated with healthcare and contain antimicrobial resistance" (143). The main objective of this programme is to strengthen the prevention and control of healthcare-associated infections (HAI) and to content the AMR, looking to decrease their incidence and consequences to the health system and the patients (144).

Regarding infection prevention, this programme has four central points: strengthen the prevention and control culture on HAI, develop a strategy in hand hygiene among the healthcare sector, disrupt the microbe transmission between healthcare workers, patients and families, and control of environmental hazards related to HAI and AMR. Besides, this programme aims to improve education and training in infection prevention strategies for health workers. The implementation of this programme is expected to be finished by 2021 (144).

Vaccination is an effective way to reduce AMR by the prevention of infectious diseases that need antimicrobials to be treated. This reduction is due to the decrease in the prevalence of viral infections (these can be erroneously treated with antibiotics or can lead to concomitant bacterial infections needing antibiotic treatment), and the prevention of untreatable or hard-to-treat infections; this latter thanks to the development of new vaccines or the improvement of the existent ones (142). Colombia has coverage rates above 90% for all the vaccines under recommendation by the Expanded Programme on Immunization (EPI) (145).

6.2 Animal Infection Prevention

As a producer of meat and animal products, Colombia developed and executed official programmes to control and eradicate animal infections. For this target, the Colombian Agricultural Institute implemented several both vaccination and infection treatment programmes, such as wild origin rabies, aphthous fever, brucellosis, bovine tuberculosis, Newcastle disease, salmonellosis and classical swine fever (146). Additionally, since 2007, there are two resolutions from the ICA, regulating the sanitary conditions and welfare of the cattle, buffalo and porcine livestock destined for human consumption (147,148). The National Plan for Response to Antimicrobial Resistance search to strengthen these programmes and to continue with its implementation (76).

Chapter 7: Regulation for Antibiotics Access and Use and Antimicrobial Resistance Surveillance in Colombia

7.1 Regulations in Access and Use of Antibiotics in Human and Animal Health

Since 2005, Colombia began to regulate antibiotic sales and the prescriptions aiming to control AMR and strengthen the surveillance programmes in human health (149,150). The Colombian government had released several decrees and regulations as a way to improve prescription practices, the free sales of antibiotics and the quality of the antibiotic drugs (Table 4). After one year of the implementation of these regulations, the total antibiotic consumption decreased in 3 DID (9,16 DID to 6,76 DID), mainly in the penicillin group (82).

Regulation	Description
Documents approved by the National Council of Economic and Social Policy (CONPES), 2012.	Establish the National Pharmaceutical Policy: CONPES 155: "This policy proposes ten strategies that seek to improve access, opportunity for dispensing, quality and proper use depending on the needs of the population regardless of their payment capacity".
Decree 709 of 1991, Ministry of Health	Regulates the production and market of generic medicines, and demands quality control of these ones
Decree 677 of 1995, Ministry of Health	Regulates partially the license to medications, quality control and sanitary surveillance, and the proper purchase of antibiotics
Decree 2200 of 2005, Ministry of Health	Regulates the pharmaceutical services, including the use of prescription as mandatory in antibiotic purchasing
Decree 3050 of 2005, Ministry of Health	Regulates the antibiotic purchase only in pharmacies and under medical prescription
Decree 3518 of 2006, Ministry of Health	Creates and regulates the Public Health Surveillance System (SIVIGILA) of the Health National Institute
Circular 045 of 2012, Ministry of Health	Implements the Public Health Surveillance Strategy of Infections Associated with Healthcare, Antimicrobial Resistance and Consumption
Resolution 1160 of 2016, Ministry of Health	Adopts the Good Manufacturing Practice Manuals and Guides for Inspection of Laboratories or Drug Production Establishments for local and foreign pharmaceutical companies who have market in the country

*CONPES: National Council for Economic and Social Policy

Table 4: Regulations and restrictions of antibiotic production, access and use in humans in Colombia (119,149–155)

For animal health and food production, there are several regulations as well (Table 5), including the prohibition in the use of antibiotics as a growth factor, the control in the veterinary use of antibiotics and the need of a veterinarian prescription to acquire an antimicrobial on the animal market (76). Therefore, about the antibiotic market for veterinary use, there are not any updated restrictions, and the current ones are not followed as well. Also, there is not an adequate register of the sanitary conditions in the agricultural sector or periodic surveillance of infection prevention measures on the farms. As a consequence, the livestock owners and food producers still use large amounts of antibiotics without measuring the risk of exposure to these medicines in the animals (102). These actions have, as an outcome, the presence of antibiotics in livestock products and the appearance of AMR on farms, as it was previously described.

Regulation	Description
Documents approved by the National Council of Economic and Social Policy (CONPES).	Establish the sanitary policy and harmlessness of animal food for: CONPES 3376: Meat beef and milk CONPES 3458: Pork meat CONPES 3468: Poultry products CONPES 155: National Pharmaceutical Policy
Resolution 1326 of 1981, Colombian Agricultural Institute (ICA)	Regulates the use and market of antimicrobials in veterinary use
Resolution 1966 of 1984, Colombian Agricultural Institute (ICA)	Regulates the use of antibiotics as growth factor or enhancers of food efficiency
Resolution 1082 of 1995, Colombian Agricultural Institute (ICA)	Bans the use and market of Furazolidone, Nitrofurazone and Furaltadone for animal use.
Decree 616 of 2006, Ministry of Health	Regulates the milk production for human consumption, including antibiotic use, levels on the milk and antibiotic withdrawal times
Resolution 2341 of 2006 Resolution 2640 of 2007 Colombian Agricultural Institute (ICA)	Regulates the sanitary conditions and welfare in the meat production from cattle, buffalo and pigs intended to slaughter for human consume, including the use of antibiotics in the livestock
Resolution 3585 of 2008, Colombian Agricultural Institute (ICA)	Restriction of antibiotics as growth promoters if those antibiotics are used in human and animal health
Resolution 1382 of 2013, Ministry of Health	Establish the maximum limits of antibiotic waste and other veterinary drugs in the food of animal origin to human consumption
Resolution 22747 of 2018, Colombian Agricultural Institute (ICA)	Bans the trade, production, market and use of additives with polymyxin E (colistin) and polymyxin B as growth factors in livestock

*CONPES: National Council for Economic and Social Policy

Table 5: Regulations and restrictions of antibiotic use in agriculture and livestock production in Colombia (adapted from Arenas et al, 2018) (95,102)

7.2 Surveillance Programmes in Colombia

7.2.1 Antimicrobial Use and Infection in Humans

The INS has four main programmes in infection surveillance, managed by its Microbiology Group, including the surveillance of AMR strains of several microbes like *N gonorrhoea, S pneumoniae, Salmonella spp, Shigella spp, S aureus* among other (76) (Figure 6). Also, the country counts with several independent surveillance groups, mainly supported by universities and clinics, that provide surveillance data, information about resistance patterns, antibiotic treatment suggestions, outbreak analysis and stewardship actions (156).

Moreover, under the management of the INS, every health care facility, public or private, is responsible for generating, monthly, an AMR report (Table 6) using the WHONET software, developed by the WHO Collaborating Centre for Surveillance of Antimicrobial Resistance (157). This software allows to enhance and unify the local use of data according to local needs and promotes the exchange of data between local, national, regional and global collaborations (158). Furthermore, every year since 2015, the INS release a surveillance report of AMR in HAI using WHONET and National Laboratory data.

Staphylococcus aureus	Staphylococcus epidermidis*
Enterococcus faecalis	Enterococcus faecium
Escherichia coli	Klebsiella pneumoniae
Enterobacter cloacae	Pseudomonas aeruginosa
Acinetobacter baumannii	

* Neonatal and paediatric intensive care units

Table 6: Bacteria under surveillance in Colombia (157)



Figure 6: AMR surveillance programmes and pathogens included in the surveillance system of the INS Microbiology Group (76)
SIREVA II: Surveillance Network System for Bacterial Agents Responsible for Pneumonia and Meningitis
EDA: Enfermedad diarréica aguda
ETA: Enfermedad transmitida por alimentos

Colombia is part of the ReLAVRA network. This network was established in 1996 by the WHO/PAHO regional office and its partner states. The goal was "to inform AMR prevention and control policies and interventions in the region, through the ongoing collection of reliable, comparable and reproducible AMR data" (159). In this network, each country is represented by a national reference laboratory. In the case of Colombia is represented by the INS Laboratory. All the aggregate data on AMR is collected and reported annually, according to pre-established pathogens-drug combinations (159). ReLAVRA works in partnership with WHO Global Antimicrobial Resistance Surveillance System (GLASS), an AMR surveillance system launched by WHO in 2015, to support the global surveillance on AMR, assist in research to improve its evidence and help to inform decision-making in regards to AMR (160). Currently, ReLAVRA only executes surveillance for *Acinetobacter baumannii, Pseudomonas aeruginosa* and *Enterobacteriaceae*, but it is expected the inclusion of other bacteria on further updates (161).

Additionally, Colombia is a participant in other international surveillance programmes, named PulseNet, and WHO Global Foodborne Infections Network (80). PulseNet is a national laboratory network that detects outbreaks using the DNA fingerprint of bacteria in foodborne illness cases by *Salmonella, Listeria, Campylobacter, E coli, Vibrio* and *Shigella*. The network was constituted by the US CDC and comprised 86 laboratories worldwide (162). This data is used for surveillance and outbreak identification, antimicrobial resistance trends, source attribution, transmission patterns and other features (162).

The WHO's Global Foodborne Infections Network (GFN) is a surveillance laboratory network in charge of detecting, responding and preventing foodborne and enteric infections (163). This network in a partnership with the Advisory Group on Integrated Surveillance of Antimicrobial Resistance (AGISAR), who developed the guidelines in Integrated Surveillance of Antimicrobial Resistance in Foodborne Bacteria, guidelines that followed the One Health approach to collect, validate, analyse and report data on AMR in foodborne bacteria from animals, humans, food and antimicrobial use (164).

7.2.2 Antimicrobial Use and Infection in Animals

Among the LMIC, Colombia is the only country with AMR surveillance data in animals publicly available (54). Due to the fragmentation and the lack of AMR data in animals, in 2007 several Colombian organizations decided to constitute a 4-years pilot of a system of integrated surveillance in AMR named COIPARS (Colombian Integrated Program for Antimicrobial Resistance Surveillance). Before this system was established, there was not any formal integrated surveillance system in animal AMR at a national level; only the Colombian Agricultural Institute had information about drug-resistant bacterial isolates in different animal species around the country, together with INVIMA, who had some analysis of AMR in bacterial isolates in food from animal production (83)

COIPARS was established to meet the requirement of the animal industry regarding animal health and welfare and address the ideas and concerns about AMR of animal origin in public health. As an outcome, the food safety of products from livestock should be assured. This system received advice from WHO/PAHO; the Canadian Integrated Program for Antimicrobial Resistance (CIPARS), the Danish Integrated Antimicrobial Resistance Monitoring and Research Programme (DANMAP), the National Antimicrobial Resistance Monitoring System for Enteric Bacteria of the CDC (CDC-NARMS) and the University of California (83). As there was not any surveillance system on animal AMR in Latin America, the collaboration has to be with HIC surveillance systems.

Several stakeholders were included in this AMR system, including public and private ones, that make part of the Colombian government, universities, animal food retailers and the poultry industry. All the scientific evidence and support were provided by AGROSAVIA (before called CORPOICA), a decentralised public entity (83).

As the COIPARS system was only focused in the poultry industry and stopped working around 2012, in 2019 the Colombian Agricultural Institute (ICA) designed the Surveillance and Monitoring Program for Resistance to Antimicrobial Agents, which includes the primary livestock production. This programme is aligned with the National Antimicrobial Resistance Response Plan and is based on the lineament of the tripartite alliance for AMR WHO-FAO-OIE. The programme is still in its implementation phase (165).

Chapter 8: Discussion

The One Health approach allows a broad perspective about the AMR situation and its impact on global health, economy, ecology, food security, and other areas. The importance of the interaction between animals, the environment and humans to understand the AMR challenge, makes One Health the proper strategy to develop innovative solutions against this global problem. Knowledge about One Health is increasing in Colombia, but more work on the spread of the approach is required to get the expected outcome of integrating human, animal and environmental health.

Regarding the AMR status in Colombia, data remains fragmented and limited. There is not disaggregate data about AMR mortality in the country or its economic and social impact. Also, there is not enough data about the AMR trends between regions and among urban and rural populations, where the access to antimicrobials is still easy. This fragmentation of the data can be seen in the animal sector as well, where the data regarding AMR is focused mainly on the poultry industry, maybe due to the lack of an organized AMR surveillance and reporting system for the cattle and pig industry.

The lack of information and regulations about antibiotic production and quality in Colombia was another finding made by this review. The different bioequivalence between branded and generic antibiotics can contribute to AMR, and also the therapeutic non-equivalence, finding reported for several antibiotics and without any action taken by the INVIMA, stakeholder that remains reluctant to include antibiotics on the list of medicines with mandatory bioequivalence study before their release to the market.

The easy access to antibiotics is a driven action for high antibiotic use. Although the sales of antibiotics for the general population are regulated, drugstores' workers are still avoiding these rules and keeping the sales of antibiotics without any prescription. This practice is common in veterinary stores as well. The easy access can lead to the self-prescription of antibiotics, the household "drug stock" and the wrong use of antibiotics as a treatment for non-bacterial infections or non-infectious diseases, practices that will be addressed later. On animal health, the easy access to antibiotics by meat producers is also a common practice, as well as the lack of knowledge about the proper antibiotic use and the correct withdrawal times to assure safety and uncontaminated meat.

Access to antibiotics without prescription despite the regulation in the purchasing is common in other LMICs. Two systematic reviews in LMICs about self-prescription of antibiotics showed this practice was related to both inadequate implementation and lack of awareness about the restrictions for the antibiotics purchase, and also with cultural differences (166,167). Additionally, the willingness of the pharmacist to sell antibiotics without prescription and to give recommendations about the type of antibiotic for purchase is common among LMICs, where the inappropriate prescription of antibiotics was usual (166,167), similarities shared with Colombia as well.

The knowledge about adequate antibiotic use is an important factor that can contribute to tackling the AMR problem. Unfortunately, data showed Colombian medical doctors are not well prepared in the prescription of antibiotics and interpretation of diagnostic tools for infectious diseases once they finish their academic cycle; and as the CME is not mandatory, the updated knowledge and practices are not evenly distributed among the medical doctors. Probably doctors that live in urban areas and work in big hospitals and clinics have more willingness to use the academic tools and to follow the local or international guidelines. On the other hand, there is no data published regarding the knowledge about antibiotic use and prescription practices among veterinarians in Colombia.

A survey made among EU/EEA healthcare workers about their knowledge, attitudes and behaviours on antibiotic use showed 58% of the surveyed health workers answered the questions regarding antibiotic use correctly, in contrast with 80% that said they had enough knowledge about how to use antibiotics appropriately. Also, among the surveyed workers, 66% used clinical guidelines, 40% used antibiotics following their previous clinical experience, and 33% used the knowledge acquired in CME (168). These findings showed better adherence to the guidelines, but no difference in the knowledge of antibiotic use among healthcare workers, showing the knowledge about the antibiotics is not better in countries with higher educational standards than Colombia. Also, 8% of the EU/EEA health workers prescribe antibiotics to maintain the patient relationship (168), finding that related with the 5% of the Colombian physicians that prescribe antibiotics by request of the patient's family, probably to maintain a good relationship as well, showing the relationship between patient and physician can be a drive to antibiotic misuse too.

The antibiotic use for human health in Colombia is related to the knowledge and prescription practices among the health workers, and with the access and use of antibiotics among the general population as well. In the case of antibiotic use among health facilities, data shows a decrease in the last years in comparison with previous years, when stewardship programmes on AMR and regulations were not implemented yet. Data shows a geographical variation in antibiotic misuse, as the region with the highest consumption of wide-spectrum antibiotics on the health facilities is one of the most isolated and poorest regions of Colombia; however, the main focus of infection for AMR microbes are the cities with the most significant economic and population growth. Furthermore, knowledge regarding antibiotics is a high concern for safe antibiotic use.

Data collected from others LMIC confirms the high incidence of self-prescription among the general population (134). Torres et al. in its systematic scoping review corroborate this practice, where 100% of the participants in the studies reviewed, self-medicated themselves with antibiotics in the past year before the studies (134). There is no data regarding self-medication in the Colombian rural areas, but the review confirms the high prevalence of self-medication with antibiotics in the urban areas (134), a trend that was also seen in major Colombian cities. The variation in the relationship between educational level, gender and self-medication with antibiotics was also found in other LMIC, making these factors independent variables on the practice of self-medication (134).

Therefore, the antibiotic use among the general population in Colombia cannot be determined, as the self-medication is a common practice among the Colombian population. This practice is related to easy access to antibiotics without prescription, as mentioned before. The easy access to antibiotics allows the household "drug-stock" of antibiotics, the misuse of antibiotics to treat non-bacterial infections or non-infectious diseases and the "prescription" of antibiotics from relatives and friends. These factors related to self-medication with antibiotics were found in other LMICs, proving Colombia shares the same perceptions and practices about self-prescription than countries in a similar context (134,166). The misuse of antibiotics related to nonadherence to the timing of dosage, commonly early cessation of treatment or the use of antibiotics for a shorter time than the prescribed, and the self-prescription because of past successful use are other similarities found in others LMIC, principally in Asian countries (166).

The use of antibiotics in animals as an AMR driver is more related to its use in livestock than the use in companion animals. The antibiotic use for infection prevention and as a growth factor, although questionable, it is still widely used in the livestock market. These uses of antibiotics usually are in non-therapeutic doses, as a result of the lack of knowledge about antibiotic use among the producers, veterinarians and sellers and the easy access to antibiotics without prescription, opposite to the current regulations. These antibiotics used for animal health can be easily found in the meat because the producers are not following the proper times between the last dose of the antibiotic applied to the animal and the slaughter. Data found shows the presence of AMR bacteria in the meat and dairy products, becoming the consumption of contaminated food in a transmission way to AMR bacteria between animals and humans, mainly if immunocompromised people consume the animal-source products.

The use of non-antibiotic feed additives as an alternative to antibiotics for animal health and food production can be a good strategy to reduce antibiotic use in animal farms. Studies made in tropical countries, including Colombia, showed promissory results, as the use of these products can improve the immune system performance and the growth rate in animals. These additives include yeasts, probiotics, seeds and medicinal plants and fruits like mango, banana, avocado, and cassava (169–172). The prudent use of antibiotics, better quality in the food and water and infection prevention strategies in the farms, can reduce the use of antibiotics and the rates of AMR as well, as it is the case in the Netherlands (173). Colombia should start to implement this kind of alternatives nationwide to reduce antibiotic use and improve the quality of the animal product.

Infection prevention plays an essential role in the fight against AMR, as it was established by the WHO's Global Action Plan on Antimicrobial Resistance. In this way, Colombia has made improvements on the implementation of infection prevention programmes, as part of the Public Health Decennial Plan 2012-2021, a plan that works nationwide, and the government monitors it. As those programmes are in the implementation stage, it is not easy to define its success, but the need to change the perspective of AMR in Colombia makes these programmes promising. Also, for the vaccination programmes, the national coverage rates are high, contributing to the fight against AMR.

In animal production, several infection prevention programmes are implemented, but mainly for well-established infections such as aphthous fever, brucellosis, bovine tuberculosis, wild origin rabies, and not for bacterial infections that are leading to rising AMR rates as *E coli, Campylobacter* or *S aureus*. The new National Plan for Response to Antimicrobial Resistance is looking to expand the existing programmes and improve the infection prevention strategies at the farms and meat retailers' stores. The scope of these programmes remains unclear for infections caused by *Enterobacteria spp* and other microbes.

Colombia is making a good effort in the regulation of the market, access and use of antibiotics. The policies about the antibiotic market and use in human health exist since the early 1990s when regulations about quality in both antibiotics' production and pharmaceutical services were established; in 2005, prescription became mandatory for antibiotic purchase. However, law enforcement is weak, and the regulations are not thoroughly followed, which remains as an important issue to address on the AMR fight, as the low compliance to these regulations does not allow the success of the AMR programmes. Also, the lack of awareness of these regulations is an important factor to have in mind, as "ignorance of the law excuses not". In comparison, similar countries like Chile, Venezuela and Mexico also restricted the OTC sales of antibiotics; however, only Chile has evidence of the active participation of the drug stores in the implementation of the law, together with community awareness campaigns, with a successful decrease of antibiotic consumption in the year after to the implementation of the policy (82). In this case, the community involvement in the design and implementation of the regulation plays an important role to achieve better results. Unfortunately, data shows only change in the level of consumption only the year after the regulations were implemented, suggesting that these interventions could not be sustained over time without periodical public awareness campaigns and activities to engage community and pharmacists (82).

For animal health, there are good improvements in the regulation of the antibiotic market and use. The restriction on the use of antibiotics as a growth factor such as colistin on livestock and the establishment of maximum limits of antibiotics in meat and dairy products shows how concerned the government is about antibiotic use in animals. However, these regulations are not followed, making the efforts useless. Again, the involvement of food producers, farmers and veterinarians play an important part in making these regulations works adequately.

Law enforcement needs a proper surveillance and monitoring system. Colombia is entering an era where the flow of information with other countries is very important to put aside. Since the establishment of the first surveillance programme in 1987, many improvements in report and number of microbes with mandatory report were set in place. As these surveillance systems have had their momentum in these past two decades, the number of reports of AMR are increasing and improving, but data regarding mortality and demographic impact by AMR, and antibiotic use outside healthcare facilities remains lacking. Consequent to the implementation of the WHONET software, AMR reporting is improving, but information about demographic impact and antibiotic use among the general population remains unknown.

ReLAVRA, the regional surveillance network, only included three bacteria in its scope. Belonging to this surveillance network allows the Colombian authorities to watch the regional trends and be aware of probable outbreaks and threats in the region, where AMR bacteria can come to Colombia through travel from countries with weaker AMR programmes and higher AMR burden. The other surveillance programmes in which Colombia is an active member have not enough data published about AMR in the country.

As it was said before, among the LMICs, Colombia is the only country with AMR surveillance data published about animals. This data was collected following a pilot surveillance programme for the poultry industry, and data regarding AMR in other livestock remains fragmented or unknown. In 2019, a surveillance programme in antimicrobial agents in animals was designed and nowadays is in the implementation stage. This programme can help to watch the AMR bacteria trends in livestock and improve the numbers, but surveillance about the quantity of antibiotics used and ways to improve the regulation is still missing. Colombia does not know how much antibiotic is used in animal production, therapeutic tool or feed additive.

8.1 Relevance of the analytical framework

The analytical framework used for this thesis was helpful to analyse the AMR problem in Colombia. The framework allows the understanding of all the determinants for AMR using the One Health approach. The absence of environmental health in the framework did not represent a problem to use it, as the environmental health was not in the scope of this thesis, but this element could be added to subsequent studies if their scope includes the environment as a factor. One strength of this framework is the inclusion of knowledge as an essential factor in the study of the drivers for AMR; as the inclusion of the surveillance and monitoring systems to address the AMR problem as well.

8.2 Strengths and Limitations

The limitations of this study were several. First, the lack of data regarding antibiotic use in outside healthcare facilities, together with the fragmented data existent about epidemiology in AMR and its demographic trends. Secondly, as the National Plan for Response to Antimicrobial Resistance is on its implementation stage, it was not possible to evaluate how its implementation works on AMR trends, antibiotics access and use and law enforcement. Another review in five or ten years can show us the difference in the current situation and drivers for AMR in Colombia. The lack of information about AMR, antibiotic use and surveillance in animals was another limitation of the study. Also, there is no information about antibiotic use among veterinarians and dentists, increasing the knowledge gap about prescription practices in professionals that can prescribe antibiotics as well. As the scope of this study was mainly on AMR in bacteria and the use of antibiotics, the current AMR status on other microbes and antimicrobials (antivirals, antifungals and antiparasitic) were not addressed in this study.

The strength of this study is to be the first study of its type made on AMR in Colombia. Previous studies were focused on epidemiology, surveillance or trends of AMR and antibiotic use in the country, but there is not any focused on One Health approach and embracing both animal and human health. Despite the lack of data regarding AMR, the study is the most complete made about the topic in Colombia. Forthcoming studies can use this study as a strong base about the current situation of AMR in the country in human and animal health.

Chapter 9: Conclusions and Recommendations

9.1 Conclusions

Despite the current regulations and efforts of the Colombian government, represented by the MoHSP and its related agencies, the country shows increasing rates of AMR infections among the health facilities and the community. These rates are increasing on the most common bacteria found in the cultures and among microbes set as global threads. Additionally, the AMR burden is not limited only to human health; animal health shows rising rates of AMR as well.

The rising rates of AMR in Colombia result from the low quality of generic antibiotics and the easy access to antibiotics despite the regulations forbidding the purchase of antibiotics without prescription. Besides, among health workers, the low quality of the education regarding proper antibiotic use and the low willingness to use clinical guidelines and keep knowledge up-to-date, leading to high and improper antibiotic use, as can also be seen among the general population because of self-medication, "drug-stock" of antibiotics and non-adherence to the antibiotic regimen.

Additionally, the extensive use of antibiotics in animal production for metaphylaxis and as a growth factor, the low reach of the infection prevention programmes for animal health, and the almost non-existent surveillance programme for animal infections are other factors related to the increasing AMR rates, together with the low law enforcement for the existent regulations. Moreover, the surveillance network for AMR in human health is showing good results, but more information about demographic, social and economic impact because AMR is needed.

Fortunately, since 2015 the country is trying to implement its National Plan for Response to Antimicrobial Resistance in line with the WHO Global Action Plan on Antimicrobial Resistance. This plan gives an idea of the willingness of the country to improve the current AMR burden. However, it is a long way to go. The success of the implementation of the National Plan relies on the capacity of the government in reducing the knowledge gap, strengthen law enforcement, and increase the reach and scope of the surveillance programmes. The tools are there. Now, it is time to use them.

9.2 Recommendations

Taking into consideration the findings of this study the following recommendations aim to reduce the knowledge gap in antibiotics among health professionals, improve awareness regarding AMR and antibiotic use among the community and retail drug sector, and amplify the scope and the reach of the infection prevention and surveillance programmes. There is a need to improve the data available to have better tools to tackle AMR in Colombia.

Recommendation 1: Improve education about antibiotics and its relationship with AMR among healthcare workers, veterinarians and pharmacists.
Stakeholders: Ministry of Health and Social Protection, Ministry of National Education, Colombian Medical Association, Professional Council of Veterinary Medicine and Zootechnics of Colombia, Colombian Dentists Association, Colombian Agriculture Institute, National Health Institute.

- Enforce professional education for medical doctors, dentists and veterinarians about mechanisms of action of antibiotics, interpretation of diagnostic tools for infectious diseases and adequate prescription practices.

- Encourage CME among these professionals.
- Encourage the following of clinical guidelines, national and international, for the treatment of infectious diseases.
- Encourage the use of a culture-based approach better than the syndromic approach for the treatment of infectious diseases.
- Stimulate the enhancement of the relationship between prescribers and patients/clients, to improve the communication of medical decisions and the understanding of medical recommendations.

Recommendation 2: Strengthen the awareness of the correct use of antibiotics among the general population.
Stakeholders: Ministry of Health and Social Protection, Ministry of National Education, National Health Institute.

- Production of a strong and continuous awareness campaign in proper antibiotic use and AMR using radio, TV and social media.
- Production of a continuous campaign in infection prevention strategies such as vaccination, hand hygiene and healthy lifestyle, using radio, TV and social media.
- Motivate the return and the destruction of expired medicines and uncomplete drug regimens to avoid the "drug-stock" of antibiotics.

Recommendation 3: Improve the awareness of correct antibiotic use, AMR and infection prevention strategies among farmers and meat producers.
Stakeholders: Ministry of National Education, Ministry of Agriculture and Rural Development, Colombian Agriculture Institute (ICA).

- Implement educational programmes for farmers, dairy producers and meat retailers about antibiotic use and AMR awareness.
- Encourage the non-use of antibiotics as a growth promoter.
- Encourage the use of non-pharmaceutical and environment-friendly products to improve and maintain animal health (probiotics, healthy food for animals).
- Promote healthy and clean conditions for livestock in the farms to reduce infections and therefore reduce the antibiotic use.
- Fine the producers that do not follow the withdrawal times for antibiotics or have traces of antibiotics in their products.

Recommendation 4: Expand the regulation about the production of generic antibiotics and purchasing of antibiotics without prescription
Stakeholders: Ministry of Health and Social Protection, Food and Drug Surveillance Institute of Colombia (INVIMA).

- Strengthen antibiotic stewardship for drugstores throughout routine audits for community drugstores, retailers and veterinary drugstores.
- Encourage CME about antibiotics, correct dispensation, and AMR awareness for dispensers from veterinary and human drugstores.
- Inclusion of antibiotics on the list of medicines with mandatory bioequivalence study and incentivise the execution of more therapeutic equivalence between branded and generic antibiotics.

- Fine the drugstores that sell antibiotics without prescription.

Recommendation 5: Strengthen the surveillance programmes and data-sharing between INS and research groups.

Stakeholders: Ministry of Health and Social Protection, National Health Institute (INS), Ministry of Agriculture and Rural Development, Colombian Corporation for Agricultural Research (AGROSAVIA), Colombian Institute of Agriculture (ICA), Ministry of National Education.

- Improve the quality of the AMR data by the establishment of a national surveillance network between all the independent AMR surveillance groups in hospitals, clinics, universities, veterinarian clinics and farms to keep updated the record of AMR bacteria and their resistance patterns.
- Enlarge the surveillance about antibiotic use to drug retailers, to acquire information about antibiotic consumption among the general population outside healthcare facilities.
- Establish a surveillance programme of AMR infections among community from data obtained from outpatient healthcare facilities.

Recommendation 6: Promote the use of non-antibiotic feed additives to improve animal performance in terms of growth and health.

Stakeholders: Ministry of Agriculture and Rural Development, Colombian Agriculture Institute, Colombian Corporation for Agricultural Research (AGROSAVIA), Colombian Institute of Agriculture (ICA).

- Encourage the research in the universities and research groups in non-antibiotic feed additives in animals.
- Encourage the farms to decrease or discontinue their antibiotic use in the livestock and poultry and start to use non-antibiotic feed additives as a growth factor or as an infection prevention strategy.

Although these recommendations can be developed at the same time given the regulatory momentum through which the country crosses, the recommendations were written in order of priority, from high to medium, as there is no a low priority on the fight against AMR. All the recommendations are plausible, as Colombia has the regulatory tools and the human and financial resources to carry out these recommendations adequately.

References

1. World Health Organization. Antimicrobial resistance [Internet]. 2018 [cited 2020 Jan 11]. Available from: https://www.who.int/antimicrobial-resistance/en/
2. The World Bank. Current health expenditure (% of GDP) [Internet]. Data. 2017 [cited 2020 Aug 10]. Available from: https://data.worldbank.org/indicator/SH.XPD.CHEX.GD.ZS
3. World Health Organization. Metrics: Disability-Adjusted Life Year (DALY) [Internet]. WHO. World Health Organization; 2014 [cited 2020 Aug 10]. Available from: https://www.who.int/healthinfo/global_burden_disease/metrics_daly/en/
4. World Health Organization. DALYs / YLDs definition [Internet]. WHO. World Health Organization; 2012 [cited 2020 Aug 10]. Available from: https://www.who.int/mental_health/management/depression/daly/en/
5. The World Bank. GINI index (World Bank estimate) - Colombia [Internet]. Data. 2018 [cited 2020 Jul 25]. Available from: https://data.worldbank.org/indicator/SI.POV.GINI?locations=CO
6. Cambridge University Press. Livestock [Internet]. Cambridge Dictionary. 2020 [cited 2020 Aug 10]. Available from: https://dictionary.cambridge.org/dictionary/english/livestock
7. The Editors of Encyclopaedia Britannica. Livestock [Internet]. Encyclopædia Britannica, inc. 2019 [cited 2020 Aug 10]. Available from: https://www.britannica.com/animal/livestock
8. The World Bank. Out-of-pocket expenditure (% of current health expenditure) [Internet]. Data. 2017 [cited 2020 Aug 10]. Available from: https://data.worldbank.org/indicator/SH.XPD.OOPC.CH.ZS
9. INVIMA. Medicamento de venta libre u OTC [Internet]. Medicamentos a un clic. 2019 [cited 2020 Jul 7]. Available from: http://medicamentosaunclic.gov.co/contenidos/venta_libre.aspx
10. The Editors of Encyclopaedia Britannica. Poultry [Internet]. Encyclopaedia Britannica. 2020 [cited 2020 Aug 10]. Available from: https://www.britannica.com/animal/poultry-agriculture
11. Cambridge University Press. Poultry [Internet]. Cambridge Dictionary. [cited 2020 Aug 10]. Available from: https://dictionary.cambridge.org/dictionary/english/poultry
12. O'Neill J. Antimicrobial Resistance: Tackling a crisis for the health and wealth of nations The Review on Antimicrobial Resistance Chaired. 2014;(December). Available from: https://amr-review.org/sites/default/files/AMR Review Paper - Tackling a crisis for the health and wealth of nations_1.pdf
13. The World Bank. Population growth (annual %) - Low & middle income [Internet]. The World Bank Data. 2020 [cited 2020 Jun 6]. Available from: https://data.worldbank.org/indicator/SP.POP.GROW?locations=XO
14. Departamento Administrativo Nacional de Estadística DANE. Censo Nacional de Poblacion y Vivienda 2018: Resultados [Internet]. 2019 [cited 2020 Jun 6]. Available from: https://www.dane.gov.co/files/censo2018/infografias/info-CNPC-2018total-nal-colombia.pdf
15. The World Bank. Colombia [Internet]. The World Bank Data. 2020 [cited 2020 Jun 6]. Available from: https://data.worldbank.org/country/colombia
16. Institute for Health Metrics and Evaluation. Colombia [Internet]. IHME. 2019 [cited 2020 Jun 6]. Available from: http://www.healthdata.org/colombia
17. Ines L, Casas P, Johanna A, Tolosa A, Lilian E, Rodriguez Gutiérrez A, et al. Análisis de la Situación de Salud. Colombia, 2019 [Internet]. Bogotá D.C; 2019 [cited 2020 Jun 8]. Available from: https://www.minsalud.gov.co/sites/rid/Lists/BibliotecaDigital/RIDE/VS/ED/PSP/asis-

2019-colombia.pdf
18. OECD. Gross domestic product (GDP) (Indicator) [Internet]. 2020 [cited 2020 Jun 8]. Available from: https://data.oecd.org/gdp/gross-domestic-product-gdp.htm
19. Economic Commission for Latin America and the Caribbean (ECLAC). Economic Survey of Latin America and the Caribbean: Colombia. Santiago; 2019.
20. OECD. OECD Economic Outlook 2020. Vol. 107. Paris: OECD Publishing; 2020.
21. World Health Organization. Global Health Expenditure Database [Internet]. 2017 [cited 2020 Jun 8]. Available from: https://apps.who.int/nha/database/ViewData/Indicators/en
22. Castrillón ML. Estudio sobre bioeconomía: Anexo 5 Análisis del sector farmacéutico [Internet]. Medellín; 2018 Jun [cited 2020 Jun 8]. Available from: https://www.dnp.gov.co/Crecimiento-Verde/Documents/ejes-tematicos/Bioeconomia/Informe 2/ANEXO 5_Análisis sector farmaceutico.pdf
23. Fernandez de Soto C. Avances Plan de negocios del sector farmacéutico [Internet]. Bogotá; 2019 [cited 2020 Jun 8]. Available from: http://www.andi.com.co/Uploads/4 Camilo Fernandez de Soto.pdf
24. Ministerio de Salud y Protección Social, WHO/PAHO. Colombia: Perfil Farmacéutico Nacional [Internet]. Bogotá D.C; 2012 Dec [cited 2020 Jul 25]. Available from: https://www.who.int/medicines/areas/coordination/pscp_colombia.pdf?ua=1
25. Human Rights Watch. World Report 2020: Colombia [Internet]. World Report 2020. 2020 [cited 2020 Jul 25]. Available from: https://www.hrw.org/world-report/2020/country-chapters/colombia
26. Migración Colombia. Venezolanos en Colombia corte a 30 de abril de 2020 [Internet]. Infografía. 2020 [cited 2020 Jul 25]. Available from: https://www.migracioncolombia.gov.co/infografias/venezolanos-en-colombia-corte-a-30-de-abril-de-2020
27. OECD. OECD Economic Surveys: Colombia 2019 [Internet]. OECD Publishing, editor. Paris: OECD; 2019 [cited 2020 Jul 25]. (OECD Economic Surveys: Colombia). Available from: https://www.oecd-ilibrary.org/economics/oecd-economic-surveys-colombia-2019_e4c64889-en
28. OECD. OECD Reviews of Health Systems: Colombia 2016 [Internet]. Paris: OECD Publishing; 2015. Available from: http://dx.doi.org/10.1787/9789264248908-en
29. Bernal O, Barbosa S. [Challenges of the right to health in the Colombian model]. Salud Publica Mex [Internet]. 2015;57(5):433–40. Available from: http://www.ncbi.nlm.nih.gov/pubmed/26545005
30. Ministerio de Salud y Protección Social. Cifras de aseguramiento en salud [Internet]. 2020 [cited 2020 Jul 25]. Available from: https://www.minsalud.gov.co/proteccionsocial/Paginas/cifras-aseguramiento-salud.aspx
31. OECD. Health at a Glance 2019: OECD Indicators [Internet]. Paris: OECD Publishing; 2019 [cited 2020 Jul 25]. Available from: https://doi.org/10.1787/4dd50c09-en.
32. World Health Organization. Antimicrobial resistance [Internet]. Fact sheets. 2018 [cited 2020 Jul 17]. Available from: https://www.who.int/news-room/fact-sheets/detail/antimicrobial-resistance
33. Holmes AH, Moore LSP, Sundsfjord A, Steinbakk M, Regmi S, Karkey A, et al. Understanding the mechanisms and drivers of antimicrobial resistance. Lancet. 2016;387(10014):176–87.
34. Wright GD. Q&A: Antibiotic resistance: Where does it come from and what can we do about it? [Internet]. Vol. 8, BMC Biology. BioMed Central; 2010 [cited 2020 Jul 17]. p. 123. Available from: https://bmcbiol.biomedcentral.com/articles/10.1186/1741-7007-8-123
35. Toner E, Adalja A, Gronvall GK, Cicero A, Inglesby T V. Antimicrobial resistance is a global

health emergency. Heal Secur. 2015;13(3):153–5.
36. World Health Organization. Antimicrobial Resistance: Global Report on Surveillance. Geneva; 2014.
37. Galindo-Fraga A, Villanueva-Reza M, Ochoa-Hein E. Current Challenges in Antibiotic Stewardship in Low- and Middle-Income Countries. Curr Treat Options Infect Dis. 2018;10(3):421–9.
38. Byarugaba DK. Mechanisms of Antimicrobial Resistance. In: Sosa A de J, Byarugaba DK, Amábile-Cuevas CF, Hsueh P-R, Kariuki S, Okeke IN, editors. Antimicrobial Resistance in Developing Countries [Internet]. New York, NY: Springer New York; 2010. p. 15–26. Available from: https://doi.org/10.1007/978-0-387-89370-9_2
39. McEwen SA, Collignon PJ. Antimicrobial Resistance: A One Health Perspective. Microbiol Spectr. 2017;6(2):1–26.
40. Naghavi M, Abajobir AA, Abbafati C, Abbas KM, Abd-Allah F, Abera SF, et al. Global, regional, and national age-sex specifc mortality for 264 causes of death, 1980-2016: A systematic analysis for the Global Burden of Disease Study 2016. Lancet. 2017 Sep 16;390(10100):1151–210.
41. Cassini A, Högberg LD, Plachouras D, Quattrocchi A, Hoxha A, Simonsen GS, et al. Attributable deaths and disability-adjusted life-years caused by infections with antibiotic-resistant bacteria in the EU and the European Economic Area in 2015: a population-level modelling analysis. Lancet Infect Dis. 2019 Jan 1;19(1):56–66.
42. Tacconelli E, Carrara E, Savoldi A, Kattula D, Burkert F. Global priority list of antibiotic-resistant bacteria to guide research, discovery, and development of new antibiotics [Internet]. Geneva; 2017 Feb [cited 2020 Jul 16]. Available from: http://www.cdc.gov/drugresistance/threat-report-2013/
43. Lo Yan Yam E, Yang Hsu L, Peng-Huat Yap E, Wen Yeo T, Lee V, Schlundt J, et al. Antimicrobial Resistance in the Asia Pacific region: a meeting report. Antimicrob Resist Infect Control [Internet]. 2019 [cited 2020 Jun 11];8(202). Available from: https://doi.org/10.1186/s13756-019-0654-8
44. Bhatia R. Antimicrobial Resistance in developing Asian countries: burgeoning challenge to global health security demanding innovative approaches. Glob Biosecurity [Internet]. 2019 May 2 [cited 2020 Jun 11];1(2):50. Available from: https://jglobalbiosecurity.com/article/10.31646/gbio.4/
45. Lim C, Takahashi E, Hongsuwan M, Wuthiekanun V, Thamlikitkul V, Hinjoy S, et al. Epidemiology and burden of multidrug-resistant bacterial infection in a developing country. Elife. 2016;5(e18082).
46. Bernabé KJ, Langendorf C, Ford N, Ronat JB, Murphy RA. Antimicrobial resistance in West Africa: a systematic review and meta-analysis. Int J Antimicrob Agents. 2017 Nov 1;50(5):629–39.
47. Ampaire L, Muhindo A, Orikiriza P, Mwanga-Amumpaire J, Bebell L, Boum Y. A review of antimicrobial resistance in East Africa. Afr J Lab Med. 2016;5(1).
48. Leopold SJ, van Leth F, Tarekegn H, Schultsz C. Antimicrobial drug resistance among clinically relevant bacterial isolates in sub-Saharan Africa: a systematic review. J Antimicrob Chemother [Internet]. 2014 May 30;69(9):2337–53. Available from: https://doi.org/10.1093/jac/dku176
49. UNAIDS. UNAIDS Data 2019 [Internet]. Geneva; 2019 [cited 2020 Jun 12]. Available from: https://www.unaids.org/sites/default/files/media_asset/2019-UNAIDS-data_en.pdf
50. Gregson J, Gupta RK, Gregson J, Parkin N, Haile-Selassie H, Tanuri A, et al. HIV-1 drug resistance before initiation or re-initiation of first-line antiretroviral therapy in low-income and middle-income countries: a systematic review and meta-regression analysis. Lancet Infect Dis

[Internet]. 2018 [cited 2020 Jun 12];18:346–55. Available from: www.hivfrenchresistance.org/
51. World Health Organization. World Malaria Report 2019 [Internet]. Geneva; 2019. Available from: https://www.who.int/publications-detail/world-malaria-report-2019
52. Conrad MD, Rosenthal PJ. Antimalarial drug resistance in Africa: the calm before the storm? Lancet Infect Dis. 2019 Oct;19(10):e338–51.
53. Van Boeckel TP, Brower C, Gilbert M, Grenfell BT, Levin SA, Robinson TP, et al. Global trends in antimicrobial use in food animals. Proc Natl Acad Sci U S A. 2015;112(18):5649–54.
54. Van Boeckel TP, Pires J, Silvester R, Zhao C, Song J, Criscuolo NG, et al. Global trends in antimicrobial resistance in animals in low-and middle-income countries. Science (80-) [Internet]. 2019 Sep 20 [cited 2020 Jun 12];365(eaaw1944). Available from: http://science.sciencemag.org/
55. U.S. Centers for Disease Control and Prevention. Antibiotic resistance threats in the United States, 2019. [Internet]. Atlanta; 2019. Available from: https://www.cdc.gov/drugresistance/pdf/threats-report/2019-ar-threats-report-508.pdf
56. Public Health Agency of Canada. Canadian Antimicrobial Surveillance System: Update 2018. Ottawa; 2018 Nov.
57. Red Latinoamericana de Vigilancia de la Resistencia a los Antimicrobianos. OPS/OMS | ReLAVRA - Patógenos seleccionados probados e informados por los países [Internet]. ReLAVRA. 2014 [cited 2020 Jun 15]. Available from: https://www.paho.org/hq/index.php?option=com_content&view=article&id=15345:relavra-selected-pathogens-annually-tested-reported-countries&Itemid=40388&lang=es
58. Jones RN, Guzman-Blanco M, Gales AC, Gallegos B, Castro ALL, Martino MDV, et al. Susceptibility rates in Latin American nations: Report from a regional resistance surveillance program (2011). Brazilian J Infect Dis. 2013 Nov 1;17(6):672–81.
59. Guzmán-Blanco M, Labarca JA, Villegas MV, Gotuzzo E. Extended spectrum β-lactamase producers among nosocomial Enterobacteriaceae in Latin America. Vol. 18, Brazilian Journal of Infectious Diseases. Elsevier Editora Ltda; 2014. p. 421–33.
60. U.S. Department of Health and Human Services FDA. The National Antimicrobial Resistance Monitoring System: NARMS Integrated Report, 2016-2017 [Internet]. 2019 [cited 2020 Jul 29]. Available from: https://www.fda.gov/animal-veterinary/national-antimicrobial-resistance-monitoring-system/2016-2017-narms-integrated-summary
61. One Health Initiative Task Force. One Health : A New Professional Imperative [Internet]. 2008 [cited 2020 Jun 17]. Available from: https://www.avma.org/sites/default/files/resources/onehealth_final.pdf
62. Hill-Cawthorne GA. OneHealth/EcoHealth/PlanetaryHealth and their evolution. In: Walton M, editor. One Planet, One Health [Internet]. 1st ed. Sydney: Sydney University Press; 2019 [cited 2020 Jun 18]. Available from: https://library.oapen.org/viewer/web/viewer.html?file=/bitstream/handle/20.500.12657/25284/1004812.pdf?sequence=1&isAllowed=y
63. One Health Initiative. About - One Health Initiative [Internet]. 2020 [cited 2020 Jun 17]. Available from: https://onehealthinitiative.com/about/
64. Centres for Disease Control and Prevention CDC. One Health Basics | One Health | CDC [Internet]. 2018 [cited 2020 Jun 17]. Available from: https://www.cdc.gov/onehealth/basics/index.html
65. One Health Commission. What is One Health? - One Health Commission [Internet]. 2019 [cited 2020 Jun 17]. Available from: https://www.onehealthcommission.org/en/why_one_health/what_is_one_health/

66. Destoumieux-Garzón D, Mavingui P, Boetsch G, Boissier J, Darriet F, Duboz P, et al. The One Health concept: 10 years old and a long road ahead. Front Vet Sci. 2018;5(14).
67. White A, Hughes JM. Critical Importance of a One Health Approach to Antimicrobial Resistance. Ecohealth [Internet]. 2019;16(3):404–9. Available from: https://doi.org/10.1007/s10393-019-01415-5
68. Collignon PJ, McEwen SA. One health: its importance in helping to better control antimicrobial resistance. Trop Med Infect Dis. 2019;4(1).
69. Medina M, Legido-Quigley H, Yang Hsu L. Antimicrobial Resistance in One Health. In: Masys AJ, Izurieta R, Reina Ortiz M, editors. Global Health Security: Recognizing Vulnerabilities, Creating Opportunities. 1st ed. Cham: Springer Nature Switzerland AG; 2020. p. 209–29.
70. Zurfuh K, Poirel L, Nordmann P, Nüesch-inderbinen M, Hächler H, Yy L, et al. Occurrence of the Plasmid-Borne mcr-1 Colistin Resistance Gene in River Water and Imported Vegetable Samples in Switzerland. Antimicrob Agents Chemother. 2016;60(4):2594–5.
71. Page SW, Gautier P. Use of antimicrobial agents in livestock. OIE Rev Sci Tech. 2012;31(1):145–88.
72. World Bank Group. Drug-Resistant Infections: A Threat to Our Economic Future [Internet]. Washington; 2017 [cited 2020 Jun 30]. Available from: www.worldbank.org
73. Food and Agriculture Organization of the United Nations, World Organisation for Animal Health, World Health Organization. The FAO-OIE-WHO Collaboration: Sharing responsibilities and coordinating global activities to address health risks at the animal-human-ecosystems interfaces [Internet]. 2010 [cited 2020 Aug 11]. Available from: https://www.who.int/foodsafety/zoonoses/final_concept_note_Hanoi.pdf?ua=1
74. World Health Organization. One Health [Internet]. Q&A. 2017 [cited 2020 Aug 11]. Available from: https://www.who.int/news-room/q-a-detail/one-health
75. Food and Agriculture Organization of the United Nations, World Organisation for Animal Health, World Health Organization. The Tripartite's Commitment: Providing multi-sectoral, collaborative leadership in addressing health challenges [Internet]. 2017 Oct [cited 2020 Aug 11]. Available from: www.oie.int/2010tripartitenote
76. Ministerio de Salud y Protección Social. Plan Nacional de Respuesta a la Resistencia a los Antimicrobianos - Plan Estratégico. 2018;66. Available from: https://www.minsalud.gov.co/sites/rid/Lists/BibliotecaDigital/RIDE/VS/MET/plan-respuesta-resistencia-antimicrobianos.pdf
77. Dar OA, Hasan R, Schlundt J, Harbarth S, Caleo G, Dar FK, et al. Exploring the evidence base for national and regional policy interventions to combat resistance. Lancet. 2016;387(10015):285–95.
78. Pan American Health Organization. AMR Review: The Government and the National Action Plan. Trinidad and Tobago [Internet]. 2019. Available from: https://www.paho.org/en/documents/trinidad-and-tobago-infographic-amreview-progress-implementation-national-action-plan
79. Pan American Health Organization. AMR Review: Guyana [Internet]. 2019. Available from: https://www.paho.org/es/node/63931
80. Pan American Health Organization. AMR Review: Avances en el Plan de Acción Nacional. Colombia [Internet]. 2019. Available from: https://www.paho.org/es/node/63930
81. Pan American Health Organization. AMR Review: Avances en el Plan de Acción Nacional. Argentina [Internet]. 2019. Available from: https://www.paho.org/es/node/63929
82. Wirtz VJ, Herrera-Patino JJ, Santa-Ana-Tellez Y, Dreser A, Elseviers M, Vander Stichele RH. Analysing policy interventions to prohibit over-the-counter antibiotic sales in four Latin American countries. Trop Med Int Heal. 2013;18(6):665–73.

83. Donado-Godoy P, Castellanos R, León M, Arevalo A, Clavijo V, Bernal J, et al. The Establishment of the Colombian Integrated Program for Antimicrobial Resistance Surveillance (COIPARS): A Pilot Project on Poultry Farms, Slaughterhouses and Retail Market. Zoonoses Public Health [Internet]. 2015 Apr 1 [cited 2020 Jul 2];62(s1):58–69. Available from: http://doi.wiley.com/10.1111/zph.12192
84. Corpoica. Colombian Integrated Program for Antimicrobial Resistance Surveillance COIPARS [Internet]. 2012. Available from: http://coiparsamr.wix.com/coipars#!que-es-coipars
85. Colombia - Wisconsin One Health. One Health Consortium [Internet]. 2020 [cited 2020 Jul 2]. Available from: http://www.cwonehealth.com/
86. Universidad de Córdoba. One Health Net Colombia [Internet]. 2020 [cited 2020 Jul 2]. Available from: https://www.facebook.com/OneHealthColombia/
87. Ovalle MV, Saavedra SY, González MN, Hidalgo AM, Duarte C, Beltrán M. Resultados de la vigilancia nacional de resistencia antimicrobiana en infecciones asociadas a la atención en salud en enterobacterias y Gram negativos no fermentadores, Colombia 2012-2014. Biomedica. 2017;37(4):1–39.
88. Pan American Health Organization. OPS/OMS | Plataforma de Análisis de ReLAVRA [Internet]. 2019 [cited 2020 Jul 6]. Available from: https://www.paho.org/hq/index.php?option=com_content&view=article&id=15341:relavra-visualization-1&Itemid=40388&lang=es
89. Yong D, Toleman MA, Giske CG, Cho HS, Sundman K, Lee K, et al. Characterization of a New Metallo-Lactamase Gene, bla NDM-1 , and a Novel Erythromycin Esterase Gene Carried on a Unique Genetic Structure in Klebsiella pneumoniae Sequence Type 14 from India. Antimicrob Agents Chemother [Internet]. 2009 [cited 2020 Jul 3];53(12):5046–54. Available from: http://aac.asm.org/
90. Escobar Pérez JA, Olarte Escobar NM, Castro-Cardozo B, Valderrama Márquez IA, Garzón Aguilar MI, De La Barrera LM, et al. Outbreak of NDM-1-producing Klebsiella pneumoniae in a neonatal unit in Colombia. Antimicrob Agents Chemother. 2013;57(4):1957–60.
91. Rada AM, Hernández-Gómez C, Restrepo E, Villegas MV. Distribución y caracterización molecular de betalactamasas en bacterias Gram negativas en Colombia, 2001-2016. Biomédica. 2019;39(Supl.1):199–220.
92. Escandón-Vargas K, Reyes S, Gutiérrez S, Villegas MV. The epidemiology of carbapenemases in Latin America and the Caribbean. Expert Rev Anti Infect Ther [Internet]. 2017;15(3):277–97. Available from: http://dx.doi.org/10.1080/14787210.2017.1268918
93. Mendes Oliveira VR, Paiva MC, Lima WG. Plasmid-mediated colistin resistance in Latin America and Caribbean: A systematic review. Travel Med Infect Dis [Internet]. 2019;31(February):101459. Available from: https://doi.org/10.1016/j.tmaid.2019.07.015
94. Liu YY, Wang Y, Walsh TR, Yi LX, Zhang R, Spencer J, et al. Emergence of plasmid-mediated colistin resistance mechanism MCR-1 in animals and human beings in China: A microbiological and molecular biological study. Lancet Infect Dis [Internet]. 2016;16(2):161–8. Available from: http://dx.doi.org/10.1016/S1473-3099(15)00424-7
95. Instituto Colombiano de Agricultura. Resolución 22747 de 2018 [Internet]. 2018 [cited 2020 Jul 14]. Available from: http://legal.legis.com.co/document/Index?obra=legcol&document=legcol_407296c205054b35b7d1c49db3b957a0
96. Satoh K, Makimura K, Hasumi Y, Nishiyama Y, Uchida K, Yamaguchi H. Candida auris sp. nov., a novel ascomycetous yeast isolated from the external ear canal of an inpatient in a Japanese hospital. Microbiol Immunol. 2009;53(1):41–4.
97. Parra-Giraldo CM, Valderrama SL, Cortes-Fraile G, Garzón JR, Ariza BE, Morio F, et al. First

report of sporadic cases of Candida auris in Colombia. Int J Infect Dis [Internet]. 2018;69:63–7. Available from: https://doi.org/10.1016/j.ijid.2018.01.034

98. Instituto Nacional de Salud. Alerta por emergencia global de infecciones invasivas causadas por la levadura multirresistente, Candida auris [Internet]. 2016 [cited 2020 Jul 18]. Available from: https://www.minsalud.gov.co/sites/rid/Lists/BibliotecaDigital/RIDE/IA/INS/ins-alerta-colombia-candida-auris.pdf
99. Escandón P, Cáceres DH, Espinosa-Bode A, Rivera S, Armstrong P, Vallabhaneni S, et al. Notes from the Field: Surveillance for Candida auris — Colombia, September 2016–May 2017. Morb Mortal Wkly Rep [Internet]. 2018 Apr 20 [cited 2020 Aug 1];67(15):459–60. Available from: https://doi.org/10.1016/j.jinf.2016.07.008
100. Instituto Nacional de Salud. Informe de resultados de la vigilancia por laboratorio de resistencia antimicrobiana en infecciones asociadas a la atención en salud (IAAS) 2018 [Internet]. Bogotá D.C; 2019. Available from: https://www.ins.gov.co/buscador-eventos/Informacin de laboratorio/Informe-vigilancia-por-laboratorio-resistencia-antimicrobiana-y-whonet-IAAS-2018.pdf
101. Instituto Nacional de Salud. Informe de resultados de la vigilancia por laboratorio de resistencia antimicrobiana en infecciones asociadas a la atención en salud (IAAS) 2017. Bogotá D.C; 2018.
102. Arenas NE, Melo VM. Producción pecuaria y emergencia de antibiótico resistencia en Colombia: Revisión sistemática. Infectio. 2018;22(2):110–9.
103. Vásquez-Jaramillo L, Ramírez NF, Akineden Ö, Fernández-Silva JA. Presence of extended-spectrum beta-lactamase (ESBL)-producing enterobacteriaceae in bulk-tank milk of bovine dairy farms in Antioquia, Colombia. Rev Colomb Ciencias Pecu. 2017;30(2):85–100.
104. Arenas NE, Abril DA, Valencia P, Khandige S, Soto CY, Moreno-Melo V. Screening food-borne and zoonotic pathogens associated with livestock practices in the Sumapaz region, Cundinamarca, Colombia. Trop Anim Health Prod. 2017;49(4):739–45.
105. Donado-Godoy P, Gardner I, Byrne BA, Leon M, Perez-Gutierrez E, Ovalle M V., et al. Prevalence, risk factors, and antimicrobial resistance profiles of Salmonella from commercial broiler farms in two important poultry-producing regions of Colombia. J Food Prot. 2012;75(5):874–83.
106. Astaíza Martínez JM, Benavides Melo CJ, López Córdoba MJ, Portilla Ortiz JP. Diagnóstico de los principales antibióticos recomendados para pollo de engorde (broiler) por los centros agropecuarios del municipio de Pasto, Nariño, Colombia. Rev Med Vet (Bogota). 2014;(27):99.
107. Donado-godoy P, Byrne BA, León M, Castellanos R, Vanegas C, Coral A, et al. Prevalence, resistance patterns, and risk factors for antimicrobial resistance in bacteria from retail chicken meat in Colombia. J Food Prot. 2015;78(4):751–9.
108. Access to Medicine Foundation. Antimicrobial Resistance Benchmark 2020 [Internet]. Amsterdam; 2020. Available from: www.amrbenchmark.org
109. Rodriguez CA, Agudelo M, Zuluaga AF, Vesgaa O. Impact on resistance of the use of therapeutically equivalent generics: The case of ciprofloxacin. Antimicrob Agents Chemother. 2015;59(1):53–8.
110. Agudelo M, Rodriguez CA, Pelaez CA, Vesga O. Even apparently insignificant chemical deviations among bioequivalent generic antibiotics can lead to therapeutic nonequivalence: The case of meropenem. Antimicrob Agents Chemother. 2014;58(2):1005–18.
111. Rodriguez CA, Agudelo M, Zuluaga AF, Vesga O. In vitro and in vivo comparison of the anti-staphylococcal efficacy of generic products and the innovator of oxacillin. BMC Infect Dis. 2010;10.
112. Zuluaga AF, Agudelo M, Cardeño JJ, Rodriguez CA, Vesga O. Determination of therapeutic equivalence of generic products of gentamicin in the neutropenic mouse thigh infection model.

PLoS One. 2010;5(5):1–11.
113. Vesga O, Agudelo M, Salazar BE, Rodriguez CA, Zuluaga AF. Generic vancomycin products fail in vivo despite being pharmaceutical equivalents of the innovator. Antimicrob Agents Chemother. 2010;54(8):3271–9.
114. Rodriguez CA, Agudelo M, Aguilar YA, Zuluaga AF, Vesga O. Impact on bacterial resistance of therapeutically nonequivalent generics: The case of piperacillin-tazobactam. PLoS One. 2016;11(5):1–25.
115. Gomez Rubio A. Consumo de antibioticos en el ámbito hospitalario. Colombia 2017. Bogotá D.C; 2017.
116. Instituto Nacional de Vigilancia de Medicamentos y Alimentos. Listado de medicamentos para los cuales es exigible la presentación de estudio de bioequivalencia (BE) con sus respectivos productos de referencia [Internet]. 2016 Apr [cited 2020 Jul 30]. Available from: https://www.invima.gov.co/documents/20143/453029/Listado+de+moléculas+para+la+exigencia+de+Estudio.pdf/5fde1192-521f-d508-8596-07117967e8db?t=1540932334856
117. Ministerio de Salud y Protección Social. Resolución 1124 de 2016 [Internet]. Apr 5, 2016 p. 112–6. Available from: https://www.minsalud.gov.co/sites/rid/Lists/BibliotecaDigital/RIDE/DE/DIJ/resolucion-1124-de-2016.pdf
118. López JC, Romero-Cruz A, Jimenez N. Comparación de la eficacia por bioequivalencia in vitro e in vivo entre antibacterianos genéricos e innovadores: Una revisión de la literatura. Salut Sci Spiritus. 2018;4(2):44–50.
119. Ministerio de Salud y Protección Social. Decreto 677 de 1995 [Internet]. Colombia; 1995. Available from: https://www.invima.gov.co/documents/20143/453029/decreto_677_1995.pdf
120. Vacca CP, Niño CY, Reveiz L. Restricción de la venta de antibióticos en farmacias de Bogotá, Colombia: Estudio descriptivo. Rev Panam Salud Publica/Pan Am J Public Heal. 2011;30(6):586–91.
121. Ortiz Rodríguez SP, Buitrago MT, Eslava Albarracin DG, Caro Á, Henríquez Iguarán D. Caracterización de la compra de antibióticos en droguerías de Bogotá: una mirada desde los usuarios. Investig segur soc salud. 2012;15–29.
122. Instituto Colombiano Agropecuario. Resolución 1326 de 1981 [Internet]. Jun 30, 1981. Available from: https://www.ica.gov.co/getattachment/bfd42ced-5aa1-420b-bb5b-f027ebf3d53e/1981R1326.aspx
123. Ministerio de Salud. Ley 1164 de 2007 [Internet]. Oct 3, 2007. Available from: https://www.minsalud.gov.co/Normatividad_Nuevo/LEY 1164 DE 2007.pdf
124. Álvarez Peñalosa E, Salazar López R. Estado Actual de la Educación Médica en Colombia. Medicina (B Aires). 2015 Sep;37(3):276–85.
125. Higuita-Gutiérrez LF, Molina -Garcia V, Acevedo Guiral J, Gómez Cadena L, Roncancio Villamil GE, Quiceno Jiménez JN. Knowledge regarding antibiotic use among students of three medical schools in Medellin, Colombia: a cross-sectional study. BMC Med Educ [Internet]. 2020 [cited 2020 Jul 7];20(22). Available from: https://doi.org/10.1186/s12909-020-1934-y
126. Castrillón-Spitia JD, Ocampo-Palacio A, Rivera-Echeverry CI, Londoño-Montes J, Martínez-Betancur S, Machado-Alba JE. Prescripción de antibióticos en infecciones de piel y tejidos blandos en una institución de primer nivel. CES Med [Internet]. 2018 [cited 2020 Jul 29];32(1):3–13. Available from: http://dx.doi.org/10.21615/
127. Cortes JA, Montenegro-Morillo L. Encuesta de conocimientos, actitudes y prácticas sobre el uso de antibióticos en médicos Colombianos. Infectio. 2018;22(2):94–8.
128. Machado-Alba JE, Valladales-Restrepo LF, Gaviria-Mendoza A, Machado-Duque ME,

Figueras A. Patterns of antibiotic prescription in Colombia : Are there differences between capital cities and municipalities ? Antibiotics. 2020;9(389):1–14.
129. World Health Organization. WHO Report on Surveillance of Antibiotic Consumption: 2016-2018 early implementation [Internet]. Geneva; 2018. Available from: https://apps.who.int/iris/bitstream/handle/10665/277359/9789241514880-eng.pdf
130. Wirtz VJ, Dreser A, Gonzales R. Trends in antibiotic utilization in eight Latin American countries, 1997-2007. Rev Panam Salud Publica. 2010;27(3):219–25.
131. Villalobos AP, Barrero LI, Rivera SM, Ovalle MV, Valera D. Vigilancia de infecciones asociadas a la atención en salud, resistencia bacteriana y consumo de antibióticos en hospitales de alta complejidad, Colombia, 2011. Biomedica. 2014;34(SUPPL.1):67–80.
132. Huerta-Gutiérrez R, Braga L, Camacho-Ortiz A, Díaz-Ponce H, García-Mollinedo L, Guzmán-Blanco M, et al. One-day point prevalence of healthcare-associated infections and antimicrobial use in four countries in Latin America. Int J Infect Dis [Internet]. 2019;86:157–66. Available from: https://doi.org/10.1016/j.ijid.2019.06.016
133. Okeke IN, Lamikanra A, Edelman R. Socioeconomic and behavioral factors leading to acquired bacterial resistance to antibiotics in developing countries. Emerg Infect Dis [Internet]. 1999;5(1):18–27. Available from: https://wwwnc.cdc.gov/eid/article/5/1/99-0103_article
134. Torres NF, Chibi B, Middleton LE, Solomon VP, Mashamba-Thompson TP. Evidence of factors influencing self-medication with antibiotics in low and middle-income countries: a systematic scoping review. Public Health [Internet]. 2019;168:92–101. Available from: https://doi.org/10.1016/j.puhe.2018.11.018
135. Larson E. Community Factors in the Development of Antibiotic Resistance. Annu Rev Public Health [Internet]. 2007;28(1):435–47. Available from: https://www.annualreviews.org/doi/pdf/10.1146/annurev.publhealth.28.021406.144020
136. Fajardo-Zapata ÁL, Méndez-Casallas FJ, Hernández-Niño JF, Molina LH, Tarazona AM, Nossa C, et al. La automedicación de antibióticos: Un problema de salud pública. Salud Uninorte. 2013;29(2):226–35.
137. Limaye D, Limaye V, Krause G, Fortwengel G. A Systematic Review of the Literature to Assess Self-medication. Ann Med Heal Sci Res [Internet]. 2017 [cited 2020 Jul 9];7:1–15. Available from: https://www.amhsr.org/articles/a-systematic-review-of-the-literature-to-assess-selfmedication-practices-3711.html#1
138. Machado-Alba JE, Echeverri-Cataño LF, Londoño-Builes MJ, Moreno-Gutiérrez PA, Ochoa-Orozco SA, Ruiz-Villa JO. Factores económicos, sociales y culturales asociados con automedicación. Biomédica. 2014;34(4):580–8.
139. Verma P, Kumar Samanta S. Comparative assessment of antibiotic potency loss with time and its impact on antibiotic resistance. Comp Clin Path [Internet]. 2016 Nov [cited 2020 Jul 30];25(6):1163–9. Available from: https://link-springer-com.vu-nl.idm.oclc.org/content/pdf/10.1007/s00580-016-2321-2.pdf
140. Guzman-Carrillo LE, Espitia-Yanez C, Berthel LL. Presencia De Lincomicina Como Promotor De Crecimiento En Carne De Pollo Comercializado En Supermercados De Cartagena, Colombia. Vitae. 2012;19(1):S328–30.
141. Ujueta-Rodríguez S, Araque-Marín A. Detección de residuos antimicrobianos en músculo, hígado y riñón de cerdo expendidos en Bogotá, Colombia. Rev UDCA Actual Divulg Científica. 2016;19(2):371–9.
142. World Health Organization. Global Action Plan on Antimicrobial Resistance [Internet]. 2015. Available from: https://apps.who.int/iris/bitstream/handle/10665/193736/9789241509763_eng.pdf?sequen

ce=1
143. Ministerio de Salud y Protección Social. Plan Decenal de Salud Pública 2012 - 2021: La salud en Colombia la construyes tú [Internet]. Bogotá D.C: Ministerio de Salud y Protección Social; 2013. Available from: http://www.saludcapital.gov.co/DPYS/Documents/Plan Decenal de Salud Pública.pdf
144. Ministerio de Salud y Protección Social. Programa de Prevención, Vigilancia y Control de Infecciones Asociadas a la Atención en Salud-IAAS y la Resistencia Antimicrobiana [Internet]. Bogotá; 2016. Available from: https://www.minsalud.gov.co/sites/rid/Lists/BibliotecaDigital/RIDE/VS/PP/PAI/programa-iaas-ram.pdf
145. WHO/PAHO, UNICEF. Informe de País del PAI, Colombia 2018. 2019.
146. Instituto Colombiano Agropecuario. Enfermedades Animales [Internet]. [cited 2020 Jul 14]. Available from: https://www.ica.gov.co/getdoc/58fda97c-49f5-493e-891f-ce74546c62da/enfermedades-animales.aspx
147. Instituto Colombiano Agropecuario. Resolución 2640 de 2007 [Internet]. Sep 28, 2007. Available from: https://www.ica.gov.co/getattachment/6bfd1517-10f1-415d-b8cd-3ccb06d51a8f/2640.aspx
148. Instituto Colombiano Agropecuario. Resolución 2341 de 2007 [Internet]. Aug 23, 2007. Available from: https://www.ica.gov.co/getattachment/0b5de556-cb4a-43a8-a27a-cd9a2064b1ab/2341.aspx
149. Ministerio de Salud. Decreto 2200 de 2005 [Internet]. Jun 28, 2005. Available from: http://www.suin-juriscol.gov.co/viewDocument.asp?id=1417516
150. Ministerio de Salud. Decreto 3518 de 2006 [Internet]. Oct 9, 2006. Available from: http://www.suin-juriscol.gov.co/viewDocument.asp?id=1529807
151. Dirección Nacional de Planeación, Ministerio de Salud y Protección Social. CONPES 155: Política Farmaceutica Nacional [Internet]. Bogotá D.C; 2012 Aug [cited 2020 Jul 14]. Available from: https://www.minsalud.gov.co/Documentos y Publicaciones/Politica Farmacéutica Nacional.pdf
152. Ministerio de Salud. Decreto 709 de 1991 [Internet]. Mar 12, 1991. Available from: http://www.suin-juriscol.gov.co/viewDocument.asp?ruta=Decretos/1151214
153. Ministerio de Salud. Decreto 3050 de 2005 [Internet]. Sep 1, 2005. Available from: http://www.suin-juriscol.gov.co/viewDocument.asp?id=1510303
154. Ministerio de Salud y Protección Social. Resolución 1160 de 2016 [Internet]. Apr 6, 2016. Available from: www.minsalud.gov
155. Ministerio de Salud. Circular 045 de 2012 [Internet]. 2012 [cited 2020 Jul 15]. Available from: www.ins.gov.co
156. Goff DA, Kullar R, Goldstein EJC, Gilchrist M, Nathwani D, Cheng AC, et al. A global call from five countries to collaborate in antibiotic stewardship: united we succeed, divided we might fail. Lancet Infect Dis. 2017;17(2):e56–63.
157. Instituto Nacional de Salud. Resistencia bacteriana a los antimicrobianos en el ámbito hospitalario [Internet]. Bogotá D.C; 2018. Available from: https://www.ins.gov.co/buscador-eventos/Lineamientos/PRO_Resistencia_bacteriana.pdf
158. World Health Organization. WHONET Software [Internet]. WHO. World Health Organization; 2018 [cited 2020 Jul 15]. Available from: http://www.who.int/medicines/areas/rational_use/AMR_WHONET_SOFTWARE/en/
159. Pan American Health Organization, World Health Organization. ReLAVRA [Internet]. [cited 2020 Jul 15]. Available from: https://www.paho.org/hq/index.php?option=com_content&view=article&id=6221:2017-

relavra-mas-informacion&Itemid=42432&lang=en
160. World Health Organization. Global Antimicrobial Resistance Surveillance System (GLASS) [Internet]. 2015 [cited 2020 Jul 15]. Available from: https://www.who.int/glass/en/
161. Jiménez Pearson MA, Galas M, Corso A, Hormazábal J, Duarte Valderrama C, Salgado Marcano N, et al. Consenso latinoamericano para definir, categorizar y notificar patógenos multirresistentes, con resistencia extendida o panresistentes. Rev Panam Salud Pública. 2019;43.
162. Nadon C, Van Walle I, Gerner-Smidt P, Campos J, Chinen I, Concepcion-Acevedo J, et al. PulseNet International: Vision for the implementation of whole genome sequencing (WGS) for global food-borne disease surveillance. Euro Surveill [Internet]. 2017 [cited 2020 Aug 2];22(23). Available from: https://www.eurosurveillance.org/docserver/fulltext/eurosurveillance/22/23/eurosurv-22-23-4.pdf?expires=1596401147&id=id&accname=guest&checksum=2B884532451E6778D0F5063C7B093324
163. Department of Food Safety and Zoonoses. Getting involved with the Global Foodborne Infections Network (GFN) [Internet]. Geneva; [cited 2020 Aug 2]. Available from: https://www.who.int/foodsafety/areas_work/foodborne-diseases/GFN_brochure_web2.pdf
164. World Health Organization. Integrated Surveillance of Antimicrobial Resistance in Foodborne Bacteria: Application of a One Health Approach [Internet]. Geneva; 2017 [cited 2020 Aug 2]. Available from: https://apps.who.int/iris/bitstream/handle/10665/255747/9789241512411-eng.pdf?sequence=1
165. Instituto Colombiano Agropecuario. El ICA y organismos internacionales, unidos por el uso responsable de los antibióticos [Internet]. 2019 [cited 2020 Jul 16]. Available from: https://www.ica.gov.co/noticias/el-ica-y-organismos-internacionales-unidos-por-el
166. Ocan M, Obuku EA, Bwanga F, Akena D, Richard S, Ogwal-Okeng J, et al. Household antimicrobial self-medication: a systematic review and meta-analysis of the burden, risk factors and outcomes in developing countries. BMC Public Health. 2015;15(742):1–11.
167. Morgan DJ, Okeke IN, Laxminarayan R, Perencevich EN, Weisenberg S. Non-prescription antimicrobial use worldwide: A systematic review. Lancet Infect Dis. 2011 Sep 1;11(9):692–701.
168. European Centre for Disease Prevention and Control. Survey of healthcare workers' knowledge, attitudes and behaviours on antibiotics, antibiotic use and antibiotic resistance in the EU/EEA [Internet]. Stockholm; 2019 Nov [cited 2020 Aug 3]. Available from: https://www.ecdc.europa.eu/sites/default/files/documents/survey-of-healthcare-workers-knowledge-attitudes-behaviours-on-antibiotics.pdf
169. Andrea Chávez Gómez L, López Herrera A, Eduardo Parra Suescún J. Inclusion of probiotic strains improves immune parameters in broilers Artículo original. Rev CES Med Zootec. 2015;10(2):160–9.
170. De Souza KA, Cooke RF, Schubach KM, Brandão AP, Schumaher TF, Prado IN, et al. Performance, health and physiological responses of newly weaned feedlot cattle supplemented with feed-grade antibiotics or alternative feed ingredients. Animal. 2018;12(12):2521–8.
171. Guil-Guerrero JL, Ramos L, Moreno C, Zúñiga-Paredes JC, Carlosama-Yepez M, Ruales P. Plant foods by-products as sources of health-promoting agents for animal production: A review focusing on the tropics. Agron J. 2016 Sep 1;108(5):1759–74.
172. Vase-Khavari K, Mortezavi S-H, Rasouli B, Khusro A, Salem AZM, Seidavi A. The effect of three tropical medicinal plants and superzist probiotic on growth performance, carcass characteristics, blood constitutes, immune response, and gut microflora of broiler. Trop Anim

Health Prod [Internet]. 2019 [cited 2020 Aug 4];51:33–42. Available from: https://doi.org/10.1007/s11250-018-1656-x
173. Speksnijder DC, Mevius DJ, Bruschke CJM, Wagenaar JA. Reduction of veterinary antimicrobial use in the Netherlands. The Dutch success model. Zoonoses Public Health [Internet]. 2015 Apr 1 [cited 2020 Aug 4];62(s1):79–87. Available from: https://onlinelibrary-wiley-com.vu-nl.idm.oclc.org/doi/full/10.1111/zph.12167
174. World Health Organization. AWaRe Policy Brief [Internet]. Geneva; 2019 [cited 2020 Jul 29]. Available from: https://adoptaware.org/assets/pdf/aware_policy_brief.pdf

Appendices

Appendix 1: WHO AWaRe Classification for antibiotics

The AWaRe classification (Access, Watch, Reserve) helps prescribers to make optimal antibiotic choices for common infectious syndromes in adults and children, with the aim to address the AMR challenge (Table 7) (117).

- **Access**: antibiotics that represent the first or second line for empirical treatment of common infectious syndromes. These antibiotics should be available in all settings and used appropriately.
- **Watch**: antibiotics that present a higher potential to impact AMR negatively. They are the most effective options for a limited number of well-defined clinical syndromes, but their use should be monitored and restricted to the indications.
- **Reserve**: "last-resort" antibiotics, useful against MDR or XDR resistant bacteria.

AWaRe Classification	Antimicrobial group	Antimicrobial names
Access	Tetracyclines	Tetracycline, doxycycline, minocycline, lymecycline
	Amphenicols	Chloramphenicol
	Beta-lactam - penicillin	Phenoxymethyl penicillin V, penicillin G benzatin, amoxicillin, amoxicillin + clavulanic, ampicillin, ampicillin + sulbactam, dicloxacillin
	Other beta-lactams antibacterial	Cefalexin, cefradine, cefadroxil
	Sulphonamides and trimethoprim	Trimethoprim + sulfamethoxazole
	Macrolides, lincosamides and streptogramins	Clindamycin
	Aminoglycoside antibacterial	Gentamicin, amikacin, tobramycin
	Other antibacterial	Nitrofurantoin
Watch	Others beta-lactam antibacterial	Cefuroxime, ceftriaxone, cefpodoxime
	Macrolides, lincosamides and streptogramins	Erythromycin, clarithromycin, azithromycin, spiramycin
	Quinolone antibacterial	Ciprofloxacin, norfloxacin, levofloxacin, moxifloxacin
	Other antibacterial	Vancomycin, Rifaximin
Reserve	Other antibacterial	Fosfomycin

Table 7: Antibiotics available in the Colombian health system categorized according to the WHO AWaRe classification (Adapted from Machado-Alba et al) (128,174)